[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Preat Corp\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":407},{"warningLetters":4,"total":406},[5,33,55,71,91,113,135,159,182,205,222,242,260,281,299,317,334,352,370,389],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},21644,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpreye-llc-732141-08182026\">PReye, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-118\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Melinda C. O’Rourke\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>PReye, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4855 Ward Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wheat Ridge\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80033\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-118\u003C\u002Fp>\u003Cp>To Dr. Melinda C. O’Rourke:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, PReye, LLC, FDA Establishment Identifier (FEI) 3031057987, at 4855 Ward Road, Wheat Ridge, from March 17 to 19, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during the review of your website https:\u002F\u002Fessencelaser.com\u002Fvitaminsee\u002F in June 2026. Based on our review, “PReye Vitamin SEE” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We reviewed your March 22, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm was registered as a drug repacker and produced drug products solely for distribution through the co-located med spa, Essence Laser and Wellness, which you own. Your repackaging operations consisted of a small flow hood on a desk in your office. These operations were performed in a non-certified, non-qualified flow hood within an unclassified office space that lacked a high-efficiency particulate air (HEPA) filtration system.\u003C\u002Fp>\u003Cp>You obtained bulk liquid drug and manually filled multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. The drug product was labeled with directions to use “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products were filled under unsuitable aseptic processing conditions, in that they lacked appropriate facilities, equipment, and process controls to protect the drug product from microbiological contamination.\u003C\u002Fp>\u003Cp>Your manufacturing facility, equipment, and process must be designed, and operations must be executed, to prevent contamination risks to sterile drug products (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products).\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm's quality systems are inadequate. Your firm lacked a quality unit (QU) function and associated written procedures defining QU responsibilities and controls. You failed to establish basic procedures including, but not limited to, complaint review, supplier qualification, release testing, change management, cleaning, disinfection, and deviation handling. In addition, your ophthalmic drug products lack traceability because you did not issue batch numbers for all sterile drug products manufactured since 2024.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. You failed to implement fundamental procedures and practices to ensure the safety, identity, strength, quality, and purity of your drug products. See FDA's guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “PReye Vitamin SEE” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>PReye Vitamin SEE\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fessencelaser.com\u002Fvitaminsee\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Antioxidant Vitamins provide protection against the damaging effects of UV light from sun exposure. . . . In the eye, UV light ages all the structures. Ocular surface damage, cataracts and macular degeneration are all possible effects from UV exposure and can ultimately lead to decreased vision, and blindness.”\u003C\u002Fli>\u003Cli>“Both Ascorbic Acid and Acetylcysteine have been used independently to treat pathology in the eye, including corneal alkali burns and filamentary keratitis in severe dry eye. But, never have they been combined as a vitamin supplement eyedrop to prevent eye disease related to UV exposure, including cataracts and macular degeneration.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“PReye Vitamin SEE” is a \"new drug\" under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in the labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Guidance on Drug Listing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that your firm’s drug listing for “PReye Vitamin SEE” has not been updated or certified as required and therefore has been inactivated by FDA. Please update the listing information for this drug to reflect its current status. If you no longer manufacture and distribute this drug, it must be discontinued by adding an end marketing date.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you understand CGMP requirements for sterile drugs produced by aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>Container Closure for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Formulations\u003C\u002Fp>\u003Cp>When contaminated, \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products pose a significant risk of harm because \u003Cstrong>(b)(4)\u003C\u002Fstrong> administration bypasses some of the body’s natural defenses. Irreversible damage, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> can occur, and in some cases, may progress to life-threatening systemic infection. The risk is exacerbated when \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products lack a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lack data to demonstrate that the container-closure system can prevent microbiological ingress, contamination, and proliferation.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On March 22, 2026, you communicated your commitment to cease manufacturing and distribution of PReye Vitamin SEE for the U.S. market for the future. We acknowledge your commitment to cease production of PReye Vitamin SEE drugs at this facility.\u003C\u002Fp>\u003Cp>If you plan to resume any drug manufacturing operations, including repackaging, notify this office before commencing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On May 11, 2026, FDA held a teleconference with you recommending you consider removing any batches of PReye Vitamin SEE currently in distribution from the U.S. market.\u003C\u002Fp>\u003Cp>On May 18, 2026, you issued a voluntary recall of PReye Vitamin SEE due to lack of sterility testing.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3031057987 and ATTN: Compliance Officer Nancy Scheraga in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>U.S. Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\n320-26-118\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Melinda C. O’Rourke\n\nRecipient Title\n\nOwner\n\nPReye, LLC\n\n4855 Ward Rd.\n\nWheat Ridge, CO 80033\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nAugust 18, 2026\nWARNING LETTER\nReference number: 320-26-118\nTo Dr. Melinda C. O’Rourke:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, PReye, LLC, FDA Establishment Identifier (FEI) 3031057987, at 4855 Ward Road, Wheat Ridge, from March 17 to 19, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during the review of your website https:\u002F\u002Fessencelaser.com\u002Fvitaminsee\u002F in June 2026. Based on our review, “PReye Vitamin SEE” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe reviewed your March 22, 2026, response to our Form FDA 483 in detail.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\nCGMP Violations\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 21 CFR 211.63).\nYour firm was registered as a drug repacker and produced drug products solely for distribution through the co-located med spa, Essence Laser and Wellness, which you own. Your repackaging operations consisted of a small flow hood on a desk in your office. These operations were performed in a non-certified, non-qualified flow hood within an unclassified office space that lacked a high-efficiency particulate air (HEPA) filtration system.\nYou obtained bulk liquid drug and manually filled multiple (b)(4) drug products. The drug product was labeled with directions to use “(b)(4)”. Your (b)(4) products were filled under unsuitable aseptic processing conditions, in that they lacked appropriate facilities, equipment, and process controls to protect the drug product from microbiological contamination.\nYour manufacturing facility, equipment, and process must be designed, and operations must be executed, to prevent contamination risks to sterile drug products (e.g., (b)(4) drug products).\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm's quality systems are inadequate. Your firm lacked a quality unit (QU) function and associated written procedures defining QU responsibilities and controls. You failed to establish basic procedures including, but not limited to, complaint review, supplier qualification, release testing, change management, cleaning, disinfection, and deviation handling. In addition, your ophthalmic drug products lack traceability because you did not issue batch numbers for all sterile drug products manufactured since 2024.\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. You failed to implement fundamental procedures and practices to ensure the safety, identity, strength, quality, and purity of your drug products. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nUnapproved New Drug Violations\nBased on a review of your website, “PReye Vitamin SEE” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\nPReye Vitamin SEE\nOn the webpage https:\u002F\u002Fessencelaser.com\u002Fvitaminsee\u002F:\n“Antioxidant Vitamins provide protection against the damaging effects of UV light from sun exposure. . . . In the eye, UV light ages all the structures. Ocular surface damage, cataracts and macular degeneration are all possible effects from UV exposure and can ultimately lead to decreased vision, and blindness.”\n“Both Ascorbic Acid and Acetylcysteine have been used independently to treat pathology in the eye, including corneal alkali burns and filamentary keratitis in severe dry eye. But, never have they been combined as a vitamin supplement eyedrop to prevent eye disease related to UV exposure, including cataracts and macular degeneration.”\n“PReye Vitamin SEE” is a \"new drug\" under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in the labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nAdditional Guidance on Drug Listing\nWe note that your firm’s drug listing for “PReye Vitamin SEE” has not been updated or certified as required and therefore has been inactivated by FDA. Please update the listing information for this drug to reflect its current status. If you no longer manufacture and distribute this drug, it must be discontinued by adding an end marketing date.\nAdditional Guidance on Aseptic Processing\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you understand CGMP requirements for sterile drugs produced by aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nContainer Closure for (b)(4) Formulations\nWhen contaminated, (b)(4) drug products pose a significant risk of harm because (b)(4) administration bypasses some of the body’s natural defenses. Irreversible damage, including (b)(4) can occur, and in some cases, may progress to life-threatening systemic infection. The risk is exacerbated when (b)(4) drug products lack a (b)(4) and lack data to demonstrate that the container-closure system can prevent microbiological ingress, contamination, and proliferation.\nDrug Production Ceased\nOn March 22, 2026, you communicated your commitment to cease manufacturing and distribution of PReye Vitamin SEE for the U.S. market for the future. We acknowledge your commitment to cease production of PReye Vitamin SEE drugs at this facility.\nIf you plan to resume any drug manufacturing operations, including repackaging, notify this office before commencing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action, before you pursue resolution of your firm’s compliance status with FDA.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nDrug Recall\nOn May 11, 2026, FDA held a teleconference with you recommending you consider removing any batches of PReye Vitamin SEE currently in distribution from the U.S. market.\nOn May 18, 2026, you issued a voluntary recall of PReye Vitamin SEE due to lack of sterility testing.\nConclusion\nYou are responsible for implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3031057987 and ATTN: Compliance Officer Nancy Scheraga in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters on www.FDA.gov.\nSincerely,\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nU.S. Center for Drug Evaluation and Research","PReye, LLC","preye-llc-732141-08182026","2026-09-07T05:14:13.57002+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpreye-llc-732141-08182026","2026-10-26T08:09:43.892378+00:00","Warning Letter","Issued","2026-09-01","732141","Drugs","Dr. Melinda C. O’Rourke","2026-09-07T05:14:50.666+00:00","VIA UNITED PARCEL SERVICE","320-26-118","2026-08-18",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":54,"medical_device_id":20,"response_letter_date":20},1789,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2023-10-20T15:00:00Z\">10\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-19T04:00:00Z\">10\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-vapes-665661-10192023\">Great Vapes\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Zuccaro and Mark Zuccaro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Vapes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1294 Bethel Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Columbus\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@texasgreatvapes.com\"> info@texasgreatvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 19, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Zuccaro:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Great Vapes II LLC d\u002Fb\u002Fa Great Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Berry Crunch.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300911, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKevin Zuccaro and Mark Zuccaro\n\nRecipient Title\n\nOwners\n\nGreat Vapes\n\n1294 Bethel Road\n\nColumbus, OH 43220\n\nUnited States\n\ninfo@texasgreatvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 19, 2023\n\nWARNING LETTER\n\nDear Mr. Zuccaro:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Great Vapes II LLC d\u002Fb\u002Fa Great Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Berry Crunch.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300911, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Great Vapes","great-vapes-665661-10192023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-vapes-665661-10192023","2026-10-26T08:08:49.671215+00:00","2023-10-20","665661","Tobacco","Kevin Zuccaro and Mark Zuccaro","2026-08-20T00:35:07.532+00:00","VIA UPS and Electronic Mail","2023-10-19",{"id":56,"raw":57,"subject":40,"body_html":61,"body_text":62,"firm_name":43,"letter_id":63,"created_at":45,"fei_number":20,"letter_url":64,"updated_at":65,"action_type":23,"case_status":24,"posted_date":66,"marcs_cms_no":67,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":68,"body_fetched_at":69,"delivery_method":20,"recipient_title":20,"reference_number":70,"action_taken_date":66,"medical_device_id":20,"response_letter_date":20},1880,[58,59,60,39,40,13,13,13],"\u003Ctime datetime=\"2023-08-31T19:00:00Z\">08\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-31T04:00:00Z\">08\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-vapes-664240-08312023\">Great Vapes\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2300895\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Zuccaro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Vapes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 North Bryant Avenue, Suite 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Midlothian\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76065\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Info@texasgreavapes.com\"> Info@texasgreavapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 31, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Zuccaro:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Great Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Great Vapes E-juice Cinnamon Crunch 6 Nicotine 60ml.\u003C\u002Fp>\n\n\u003Cp>The e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300895, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Reference #:\n\nER2300895\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKevin Zuccaro\n\nRecipient Title\n\nOwner\n\nGreat Vapes\n\n300 North Bryant Avenue, Suite 104\n\nMidlothian, TX 76065\n\nUnited States\n\nInfo@texasgreavapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nAugust 31, 2023\n\nWARNING LETTER\n\nDear Mr. Zuccaro:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Great Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Great Vapes E-juice Cinnamon Crunch 6 Nicotine 60ml.\n\nThe e-liquid product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300895, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","great-vapes-664240-08312023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-vapes-664240-08312023","2026-10-26T08:08:49.620942+00:00","2023-08-31","664240","Kevin Zuccaro","2026-08-20T00:43:08.955+00:00","ER2300895",{"id":72,"raw":73,"subject":78,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":20,"letter_url":84,"updated_at":85,"action_type":23,"case_status":24,"posted_date":86,"marcs_cms_no":87,"product_type":27,"closeout_date":20,"issuing_office":77,"recipient_name":88,"body_fetched_at":89,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":90,"medical_device_id":20,"response_letter_date":20},2799,[74,75,76,77,78,13,13,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-14T04:00:00Z\">03\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-trends-llc-621313-03142022\">Premier Trends LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Shabana Baig\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Premier Trends LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4 Elisa Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monroe Township\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08831-3527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 621313\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 14, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Baig:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Premier Trends LLC, FEI 3014373428, at 4 Elisa Dr, Monroe Township, NJ 08831-3527, from September 23, 2021, to September 29, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Your drug product is misbranded under Section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o) because your firm is not currently registered as required under section 510(i)(1) of the FD&amp;C Act, 21 U.S.C. § 360(i)(1). In addition, on November 30, 2020, your firm discontinued the drug listing submission for Magic Heal (NDC 72168-786-12) and it has not been relisted.\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 9, 2021, response to our Form FDA 483 in detail. Your product is labeled for intended uses, such as “\u003Cstrong>MAGIC HEAL™\u003C\u002Fstrong> is a blend of unique imported essential oils, such as Neem and Karanja that have been known for centuries for their skin protection and soothing properties,” and “\u003Cstrong>MAGIC HEAL’S\u003C\u002Fstrong> soothing aroma…and is absorbed deep into the skin to nourish the rough and cracked skin into smooth and soft skin after only a few applications.” Thus, Magic Heal is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin protectant. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with drug CGMP regulations.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test your over-the-counter (OTC) drug product, Magic Heal, for the identity and strength of each active ingredient prior to release for distribution. In addition, your firm lacked approved specifications for Magic Heal. Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug product, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003Cbr>\n• a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• a plan to ensure that products in the market are in compliance with appropriate specifications.\u003Cbr>\n• a list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making lot disposition decision, and the associated written procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test dimethicone active pharmaceutical ingredients (API) and other components, including neem oil, karanja oil, and lavender, prior to use in the manufacture of your drug product, Magic Heal. You also lacked approved specifications to assure API and other components conform with appropriate specifications for identity, strength, quality, and purity. Though you receive raw materials with a certificate of analysis from your suppliers, you have not performed appropriate incoming analysis of component lots upon receipt, including confirming the identity prior to use in production of your finished drug product. You also relied on your supplier's certificate of analysis without establishing the reliability of your component supplier's test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• the chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003Cbr>\n• a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier's certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier's results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to routinely calibrate, inspect, or check according to a written program designed to assure proper performance of and to maintain adequate written records of calibration checks and inspections of automatic, mechanical, electronic equipment, or other types of equipment, including computers, used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture your drug product, Magic Heal. You did not calibrate or verify the accuracy of the temperature-controlled function of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure the manufacturing process is controlled for each batch. In addition, you failed to calibrate or qualify the scale you used to weigh drug components.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide an evaluation of all your manufacturing equipment to ensure they are suitable for the intended use. Additionally, provide your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of equipment. This plan should ensure, among other things, prompt detection of equipment performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish and follow written procedures for the preparation of master production and control records designed to assure uniformity from batch to batch. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.186(a) and 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not prepare adequate master and batch production records for your drug product, Magic Heal. Your batch records lacked:\u003C\u002Fp>\n\n\u003Cp>• Approval signatures in conformance to a master batch record\u003Cbr>\n• Detailed manufacturing instructions\u003Cbr>\n• Identity of equipment used\u003Cbr>\n• Sampling information\u003Cbr>\n• Yield\u003C\u002Fp>\n\n\u003Cp>In addition, you made several changes to your manufacturing process without justification or change control. For example, you changed the amounts of dimethicone API and other drug components (e.g., neem oil, karanja oil, and lavender) added during manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Without adequate batch records, you cannot assure the uniformity of your drug products from batch to batch.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003Cbr>\n• a risk assessment of products released to the U.S. market without adequate and approved production and control documentation.\u003Cbr>\n• procedures you have implemented or revised to assure production records are completed as required and reviewed by your quality unit prior to release of products for distribution.\u003Cbr>\n• your updated master batch record for Magic Heal.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>5. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that all personnel are qualified for the CGMP operations they perform. For example, your co-owner stated that he is the sole proprietor of the Magic Heal formulation, had full knowledge of the process, and performed all manufacturing operations. However, you lack evidence that your co-owner has the adequate experience to perform these functions nor has received the appropriate CGMP training.\u003C\u002Fp>\n\n\u003Cp>Training is essential to ensure proper performance of job functions.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003Cbr>\n• a training plan to ensure that:\u003Cbr>\n&nbsp; o job functions and training needs are established and reviewed on an ongoing basis to monitor whether staff competencies are robust.\u003Cbr>\n&nbsp; o management responsibilities and oversight are defined.\u003Cbr>\n&nbsp; o training is conducted with sufficient frequency to assure employees maintain understanding of all applicable CGMP requirements.\u003Cbr>\n&nbsp; o all staff who conduct or supervise CGMP functions are properly trained in CGMP, so that your operations are performed in a manner that assures drug safety, identity, strength, quality, and purity.\u003Cbr>\n&nbsp; o qualified individuals perform training.\u003Cbr>\n&nbsp; o provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed.\u003Cbr>\n• an assessment of the impact of the lack of appropriate training on marketed drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Your firm failed to establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacks a quality unit (QU) and approved written procedures defining QU responsibilities and controls. In addition, your firm failed to establish adequate written responsibilities and procedures for:\u003Cbr>\n• Batch release\u003Cbr>\n• Manufacturing processes\u003Cbr>\n• Laboratory deviations and CAPAs\u003Cbr>\n• Complaints\u003Cbr>\n• Recalls\u003Cbr>\n• Handling of drug product returns and rejects\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n• a determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n• provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n• a complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n• oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of your product.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality system is inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, dated June 28, 2019, FDA cited similar CGMP observations. These findings were also communicated to you during a regulatory meeting on December 17, 2019.\u003Cbr>\nHowever, your product continues to be marketed with intended uses that renders your product a drug, and the corrective actions that you have taken in response to the December 17, 2019, regulatory meeting remain inadequate.\u003C\u002Fp>\n\n\u003Cp>Additionally, you did not propose specific remedial actions in your response to our current inspectional findings nor did you indicate whether you intend to comply with drug CGMP regulations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting drug CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding and Registration\u002FListing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the information obtained from the September 29, 2021 inspection, Premier Trends LLC (FEI 3014373428) has been identified as a drug manufacturer for Magic Heal (NDC 72168-786-12). Under section 510(i)(1) of the FD&amp;C Act (21 U.S.C. 360(i)(1)), Premier Trends LLC is required to submit registration information annually by electronic means for each establishment it owns or operates that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Premier Trends LLC has not fulfilled its registration requirement. As a result, all drugs manufactured in this establishment are misbranded under Section 502(o) of the FD&amp;C Act [21 U.S.C. 352(o)].\u003C\u002Fp>\n\n\u003Cp>In addition, the drug listing submission for Magic Heal (NDC 72168-786-12) under the name and labeler code for Premier Trends LLC (FEI 3014373428) was discontinued on November 30, 2020 and has not been recertified. This date in drug listing, refers to the expiry date of the last lot manufactured. However, Premier Trends LLC continued manufacturing Magic Heal (NDC 72168-786-12) until at least September 29, 2021, when it was inspected. Under section 510 of the FD&amp;C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Failure to properly list drug products is prohibited and will render the drugs misbranded (21 U.S.C. 331(p) and 352(o).\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Cessation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you discontinue manufacturing your OTC drug product, Magic Heal, or update your labels please inform us in writing. If you continue manufacturing this product, inform us how you will meet CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #621313 and include FEI number 3014373428.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officer Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Craig Swanson\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u002FNew Jersey District\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Shabana Baig\n\nRecipient Title\n\nPresident\u002FCo-Owner\n\nPremier Trends LLC\n\n4 Elisa Drive\n\nMonroe Township, NJ 08831-3527\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter 621313\n\nMarch 14, 2022\n\nDear Ms. Baig:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Premier Trends LLC, FEI 3014373428, at 4 Elisa Dr, Monroe Township, NJ 08831-3527, from September 23, 2021, to September 29, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nYour drug product is misbranded under Section 502(o) of the FD&C Act, 21 U.S.C. 352(o) because your firm is not currently registered as required under section 510(i)(1) of the FD&C Act, 21 U.S.C. § 360(i)(1). In addition, on November 30, 2020, your firm discontinued the drug listing submission for Magic Heal (NDC 72168-786-12) and it has not been relisted.\n\nWe reviewed your October 9, 2021, response to our Form FDA 483 in detail. Your product is labeled for intended uses, such as “MAGIC HEAL™ is a blend of unique imported essential oils, such as Neem and Karanja that have been known for centuries for their skin protection and soothing properties,” and “MAGIC HEAL’S soothing aroma…and is absorbed deep into the skin to nourish the rough and cracked skin into smooth and soft skin after only a few applications.” Thus, Magic Heal is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin protectant. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with drug CGMP regulations.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm failed to test your over-the-counter (OTC) drug product, Magic Heal, for the identity and strength of each active ingredient prior to release for distribution. In addition, your firm lacked approved specifications for Magic Heal. Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug product, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\nIn response to this letter provide:\n\n• a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• a plan to ensure that products in the market are in compliance with appropriate specifications.\n\n• a list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making lot disposition decision, and the associated written procedures.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYour firm failed to test dimethicone active pharmaceutical ingredients (API) and other components, including neem oil, karanja oil, and lavender, prior to use in the manufacture of your drug product, Magic Heal. You also lacked approved specifications to assure API and other components conform with appropriate specifications for identity, strength, quality, and purity. Though you receive raw materials with a certificate of analysis from your suppliers, you have not performed appropriate incoming analysis of component lots upon receipt, including confirming the identity prior to use in production of your finished drug product. You also relied on your supplier's certificate of analysis without establishing the reliability of your component supplier's test analyses at appropriate intervals.\n\nIn response to this letter, provide:\n\n• a comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• the chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\n\n• a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier's certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier's results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n3. Your firm failed to routinely calibrate, inspect, or check according to a written program designed to assure proper performance of and to maintain adequate written records of calibration checks and inspections of automatic, mechanical, electronic equipment, or other types of equipment, including computers, used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\n\nYou used (b)(4) to manufacture your drug product, Magic Heal. You did not calibrate or verify the accuracy of the temperature-controlled function of the (b)(4) to ensure the manufacturing process is controlled for each batch. In addition, you failed to calibrate or qualify the scale you used to weigh drug components.\n\nIn response to this letter, provide an evaluation of all your manufacturing equipment to ensure they are suitable for the intended use. Additionally, provide your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of equipment. This plan should ensure, among other things, prompt detection of equipment performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment, and improved systems for ongoing management review.\n\n4. Your firm failed to establish and follow written procedures for the preparation of master production and control records designed to assure uniformity from batch to batch. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.186(a) and 211.188).\n\nYou did not prepare adequate master and batch production records for your drug product, Magic Heal. Your batch records lacked:\n\n• Approval signatures in conformance to a master batch record\n\n• Detailed manufacturing instructions\n\n• Identity of equipment used\n\n• Sampling information\n\n• Yield\n\nIn addition, you made several changes to your manufacturing process without justification or change control. For example, you changed the amounts of dimethicone API and other drug components (e.g., neem oil, karanja oil, and lavender) added during manufacturing operations.\n\nWithout adequate batch records, you cannot assure the uniformity of your drug products from batch to batch.\n\nIn response to this letter provide:\n\n• a risk assessment of products released to the U.S. market without adequate and approved production and control documentation.\n\n• procedures you have implemented or revised to assure production records are completed as required and reviewed by your quality unit prior to release of products for distribution.\n\n• your updated master batch record for Magic Heal.\n\n5. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\n\nYou failed to ensure that all personnel are qualified for the CGMP operations they perform. For example, your co-owner stated that he is the sole proprietor of the Magic Heal formulation, had full knowledge of the process, and performed all manufacturing operations. However, you lack evidence that your co-owner has the adequate experience to perform these functions nor has received the appropriate CGMP training.\n\nTraining is essential to ensure proper performance of job functions.\n\nIn response to this letter provide:\n\n• a training plan to ensure that:\n\no job functions and training needs are established and reviewed on an ongoing basis to monitor whether staff competencies are robust.\n\no management responsibilities and oversight are defined.\n\no training is conducted with sufficient frequency to assure employees maintain understanding of all applicable CGMP requirements.\n\no all staff who conduct or supervise CGMP functions are properly trained in CGMP, so that your operations are performed in a manner that assures drug safety, identity, strength, quality, and purity.\n\no qualified individuals perform training.\n\no provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed.\n\n• an assessment of the impact of the lack of appropriate training on marketed drug products.\n\n6. Your firm failed to establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nYour firm lacks a quality unit (QU) and approved written procedures defining QU responsibilities and controls. In addition, your firm failed to establish adequate written responsibilities and procedures for:\n\n• Batch release\n\n• Manufacturing processes\n\n• Laboratory deviations and CAPAs\n\n• Complaints\n\n• Recalls\n\n• Handling of drug product returns and rejects\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• a determination of whether procedures used by your firm are robust and appropriate.\n\n• provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\n• a complete and final review of each batch and its related information before the QU disposition decision.\n\n• oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of your product.\n\nQuality System\n\nYour firm’s quality system is inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nRepeat Violations at Facility\n\nIn a previous inspection, dated June 28, 2019, FDA cited similar CGMP observations. These findings were also communicated to you during a regulatory meeting on December 17, 2019.\n\nHowever, your product continues to be marketed with intended uses that renders your product a drug, and the corrective actions that you have taken in response to the December 17, 2019, regulatory meeting remain inadequate.\n\nAdditionally, you did not propose specific remedial actions in your response to our current inspectional findings nor did you indicate whether you intend to comply with drug CGMP regulations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm and because you failed to correct repeat violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting drug CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nMisbranding and Registration\u002FListing Violations\n\nBased upon the information obtained from the September 29, 2021 inspection, Premier Trends LLC (FEI 3014373428) has been identified as a drug manufacturer for Magic Heal (NDC 72168-786-12). Under section 510(i)(1) of the FD&C Act (21 U.S.C. 360(i)(1)), Premier Trends LLC is required to submit registration information annually by electronic means for each establishment it owns or operates that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Premier Trends LLC has not fulfilled its registration requirement. As a result, all drugs manufactured in this establishment are misbranded under Section 502(o) of the FD&C Act [21 U.S.C. 352(o)].\n\nIn addition, the drug listing submission for Magic Heal (NDC 72168-786-12) under the name and labeler code for Premier Trends LLC (FEI 3014373428) was discontinued on November 30, 2020 and has not been recertified. This date in drug listing, refers to the expiry date of the last lot manufactured. However, Premier Trends LLC continued manufacturing Magic Heal (NDC 72168-786-12) until at least September 29, 2021, when it was inspected. Under section 510 of the FD&C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with FDA. Failure to properly list drug products is prohibited and will render the drugs misbranded (21 U.S.C. 331(p) and 352(o).\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nDrug Production Cessation\n\nIf you discontinue manufacturing your OTC drug product, Magic Heal, or update your labels please inform us in writing. If you continue manufacturing this product, inform us how you will meet CGMP requirements.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #621313 and include FEI number 3014373428.\n\nIf you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officer Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\n\nSincerely,\n\n\u002FS\u002F\n\nCraig Swanson\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I\u002FNew Jersey District","Premier Trends LLC","premier-trends-llc-621313-03142022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-trends-llc-621313-03142022","2026-10-26T08:09:43.55912+00:00","2022-03-22","621313","Ms. Shabana Baig","2026-08-20T02:05:21.62+00:00","2022-03-14",{"id":92,"raw":93,"subject":98,"body_html":99,"body_text":100,"firm_name":101,"letter_id":102,"created_at":103,"fei_number":20,"letter_url":104,"updated_at":105,"action_type":23,"case_status":24,"posted_date":106,"marcs_cms_no":107,"product_type":108,"closeout_date":20,"issuing_office":97,"recipient_name":109,"body_fetched_at":110,"delivery_method":111,"recipient_title":20,"reference_number":20,"action_taken_date":112,"medical_device_id":20,"response_letter_date":20},157,[94,95,96,97,98,13,13,13],"\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-24T04:00:00Z\">04\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-one-trading-inc-728716-04242026\">Great One Trading Inc. \u003C\u002Fa>","Office of Inspections and Investigations","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Johnny Lau\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice-President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great One Trading Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4120 2nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11232-3315\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:GREATONEUSA@GMAIL.COM\"> GREATONEUSA@GMAIL.COM\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 728716\u003C\u002Fp>\u003Cp>Dear Johnny Lau:\u003C\u002Fp>\u003Cp>On March 27, 2026, through April 09,2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great One Trading Inc. located at 4120 2nd Ave, Brooklyn, NY 11232-3315. We also conducted an inspection on March 28, 2025. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to FDA 483a issued on April 09, 2026.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cp>Fresh Soy Chip imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>White Lotus Seed Paste w\u002FYolks Mooncake imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>Sesame Tapioca Cracker imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Jananiga Vanniyasingam, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Jananiga.vanniyasingam@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vanniyasingam via email at Jananiga.vanniyasingam@fda.hhs.gov. Please reference CMS # 728716 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJohnny Lau\n\nRecipient Title\n\nVice-President\n\nGreat One Trading Inc.\n\n4120 2nd Ave\n\nBrooklyn, NY 11232-3315\n\nUnited States\n\nGREATONEUSA@GMAIL.COM\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nWARNING LETTER\nRE: CMS# 728716\nDear Johnny Lau:\nOn March 27, 2026, through April 09,2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great One Trading Inc. located at 4120 2nd Ave, Brooklyn, NY 11232-3315. We also conducted an inspection on March 28, 2025. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to FDA 483a issued on April 09, 2026.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nFresh Soy Chip imported from (b)(4) located in (b)(4).\nWhite Lotus Seed Paste w\u002FYolks Mooncake imported from (b)(4), located in (b)(4).\nSesame Tapioca Cracker imported from (b)(4), located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Jananiga Vanniyasingam, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Jananiga.vanniyasingam@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vanniyasingam via email at Jananiga.vanniyasingam@fda.hhs.gov. Please reference CMS # 728716 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Imports","Great One Trading Inc.","great-one-trading-inc-728716-04242026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-one-trading-inc-728716-04242026","2026-10-26T08:08:49.529263+00:00","2026-05-19","728716","Food & Beverages","Johnny Lau","2026-08-19T04:41:11.515+00:00","Via Email","2026-04-24",{"id":114,"raw":115,"subject":120,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":20,"letter_url":126,"updated_at":127,"action_type":23,"case_status":24,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":20,"issuing_office":119,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":20,"reference_number":20,"action_taken_date":134,"medical_device_id":20,"response_letter_date":20},1097,[116,117,118,119,120,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:00:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-09T05:00:00Z\">12\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024\">Phillips Precision, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeanne M. Phillips\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Phillips Precision, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7 Paul Kohner Pl\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmwood Park\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07407\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 697119\u003C\u002Fp>\u003Cp>December 9, 2024\u003C\u002Fp>\u003Cp>Dear Ms. Jeanne M. Phillips:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes. For example:\u003C\u002Fp>\u003Cp>A. Cleaning validations conducted for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” used to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean orthopedic implants and instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\u003C\u002Fp>\u003Cp>1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge \u003Cstrong>(b)(4)\u003C\u002Fstrong> as all loads were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong>; system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality above \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002F cm; clean time below \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes; and load weight above \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes as well as document the degassing time during OQ.\u003C\u002Fp>\u003Cp>In addition, you executed work orders during OQ without the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\u003C\u002Fp>\u003Cp>Furthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\u003C\u002Fp>\u003Cp>iii. You failed to define or document the load configuration for work orders 65926 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 64205 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 63988 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65917 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices), 65921 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>75 devices), and 65791 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> which is allowed in section 5.2.4.2.6 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101881) enclosed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151) placed on top of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, neither of which were evaluated during OQ.\u003C\u002Fp>\u003Cp>2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” conducted under “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\u003C\u002Fp>\u003Cp>i. As specified in section 5.2.2 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality of the rinse tank is below (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) during normal operation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner. However, you failed to conduct PQ under normal operating conditions for system \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality in that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> runs were run at ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm while the remaining cycles were run at \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\u003C\u002Fp>\u003Cp>ii. You failed to utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, assembly, machine, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, these processes were not represented in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> utilized during your PQ and your firm did not document justification for the equivalency of those \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> through objective evidence.\u003C\u002Fp>\u003Cp>3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, per section 10.4 of the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable \u003Cstrong>(b)(4)\u003C\u002Fstrong> states @ \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>***.” However, you assigned a severity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; \u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4) \u003C\u002Fstrong>instruments for Customer \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\u003C\u002Fp>\u003Cp>1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe devices which had already been cleaned on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”.\u003C\u002Fp>\u003Cp>2. The “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> during manufacturing) or documented justification for why validation of such devices was not necessary.\u003C\u002Fp>\u003Cp>C. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. For example:\u003C\u002Fp>\u003Cp>1. Your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested per lot for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively and the number of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units tested for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per lot would have required testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples per lot for each test.\u003C\u002Fp>\u003Cp>2. Your “Validation Plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> unless otherwise specified, cytotoxicity testing was only conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot and endotoxicity and particulate testing was conducted on \u003Cstrong>(b)(4)\u003C\u002Fstrong> per lot. An AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong> would have required a sufficient number of samples to be able to test a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples each for endotoxins, cytotoxicity, and particulates for a lot size between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the OQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong>; removal of any adhesives; load configurations; comingling; multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process \u003Cstrong>(b)(4)\u003C\u002Fstrong> instead of actual products during OQ.\u003C\u002Fp>\u003Cp>With regards to PQ for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you dispute that \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity of the rinse tank was not conducted at nominal; however, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle was not done under normal operating conditions. You plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, there was no corrective action identified to run system \u003Cstrong>(b)(4)\u003C\u002Fstrong> purity under normal operating conditions (≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> microsiemens\u002Fcm) and define the optimal degassing time.\u003C\u002Fp>\u003Cp>With regards to the PFMEA for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you intend to review and update the existing PFMEA as needed; contact \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\u003C\u002Fp>\u003Cp>With regards to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to “amend” the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\u003C\u002Fp>\u003Cp>With regards to process validation for additional post-production cleaning processes, you state that the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and (medical grade) \u003Cstrong>(b)(4)\u003C\u002Fstrong> to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\u003C\u002Fp>\u003Cp>With regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and amendment of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation will utilize a statistically valid sampling plan based on documented rationale.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\u003C\u002Fp>\u003Cp>A. You failed to implement section 5.2.4.2.5 which states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 101395) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 99014) in the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> load.\u003C\u002Fp>\u003Cp>B. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: \u003Cstrong>(b)(4)\u003C\u002Fstrong> release instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98145) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; WO 98151), which appeared be stacked in 3 layers. In addition, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" manual specifically states that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that challenges comingling will address the original purpose which was to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as noted in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. You have not defined and documented procedures to monitor and control the following parameters for the validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> top customers:\u003C\u002Fp>\u003Cp>1. \u003Cu>Weight of the Load \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu>:\u003C\u002Fu> There is no procedure to ensure that the load \u003Cstrong>(b)(4)\u003C\u002Fstrong> weight is below \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>2. \u003Cu>Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks:\u003C\u002Fu> There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉, which was determined to be the limit during validation.\u003C\u002Fp>\u003Cp>3. \u003Cu>Concentration of the Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>4. \u003Cu>Time for Degassing of Cleaning Solution (i.e., Detergent):\u003C\u002Fu> There is no procedure to ensure that your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, which operates at \u003Cstrong>(b)(4)\u003C\u002Fstrong>kHz, is degassed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\u003C\u002Fp>\u003Cp>B. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ to \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and documentation of the temperature on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% (\u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the loads run on your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” were performed at out of specification temperatures. For example, your employees operated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner at temperatures lower than the minimum specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> orthopedic devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong> implants and \u003Cstrong>(b)(4)\u003C\u002Fstrong> surgical instruments).\u003C\u002Fp>\u003Cp>C. You have not established a procedure for the monitoring and control of temperature and time for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Section 6.2 of your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***\u003Cstrong>(b)(4)\u003C\u002Fstrong> is pre-heated***between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> F for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to application.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”; update the frequency as needed; and revise the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\u003C\u002Fp>\u003Cp>With regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning action only begins to deteriorate when temperatures go above certain limits (typically \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below \u003Cstrong>(b)(4)\u003C\u002Fstrong>℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\u003C\u002Fp>\u003Cp>You also plan to update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner.\u003C\u002Fp>\u003Cp>With regards to the inadequate monitoring and control of parameters for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to review the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation and establish the applicable monitoring and control and amend the \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure to these said controls.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\u003C\u002Fp>\u003Cp>1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for \u003Cstrong>(b)(4)\u003C\u002Fstrong> blades received with metal debris, leftover burrs, and residue corresponding to \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), the corrective actions included (1) increasing clean time to \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes for your in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning machines; (2) verifying use of the custom \u003Cstrong>(b)(4)\u003C\u002Fstrong> fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\u003C\u002Fp>\u003Cp>2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, may have affected other devices with similar geometries which also use the in-process \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines to remove residue and metal shards.\u003C\u002Fp>\u003Cp>3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>” on at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\u003C\u002Fp>\u003Cp>B. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\u003C\u002Fp>\u003Cp>1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Rejection % (Score: \u003Cstrong>(b)(4)\u003C\u002Fstrong>); Occurrence (Score \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and Detectability (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). A combined score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Almost Certain” while a score of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\u003C\u002Fp>\u003Cp>2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\u003C\u002Fp>\u003Cp>3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across \u003Cstrong>(b)(4)\u003C\u002Fstrong> unique part numbers.\u003C\u002Fp>\u003Cp>4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate.\u003C\u002Fp>\u003Cp>With regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\u003C\u002Fp>\u003Cp>With regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples \u003Cstrong>(b)(4)\u003C\u002Fstrong> orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for \u003Cstrong>(b)(4)\u003C\u002Fstrong> associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\u003C\u002Fp>\u003Cp>With regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> not lowest score \u003Cstrong>(b)(4)\u003C\u002Fstrong> and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\u003C\u002Fp>\u003Cp>With regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\u003C\u002Fp>\u003Cp>You have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\u003C\u002Fp>\u003Cp>A. \u003Cu>Internal Nonconformances, found during manufacturing and inspections (excluding \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections\u003C\u002Fu> – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\u003C\u002Fp>\u003Cp>B. \u003Cu>Internal nonconformances, only found during \u003C\u002Fu>\u003Cstrong>\u003Cu>(b)(4)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cu> inspections conducted during manufacturing\u003C\u002Fu> – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal \u003Cstrong>(b)(4)\u003C\u002Fstrong> Scrap Log” and then discards the part along with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Acceptance Number Sampling Plan Fifth Edition” which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling. For example:\u003C\u002Fp>\u003Cp>A. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>), your personnel only used your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to measure the critical diameter feature \u003Cstrong>(b)(4)\u003C\u002Fstrong> times (to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured \u003Cstrong>(b)(4)\u003C\u002Fstrong> times at \u003Cstrong>(b)(4)\u003C\u002Fstrong> since the inspection plan was specified to follow the Acceptable Quality Limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (AQL \u003Cstrong>(b)(4)\u003C\u002Fstrong>) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices being returned and scrapped due to diameters exceeding the specified limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> +\u002F- \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. On 5\u002F17\u002F24, our investigator observed employee \u003Cstrong>(b)(4)\u003C\u002Fstrong> operate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for machining of the metal locking date ring (Part # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) under WO # 102106. Your operator explained that every \u003Cstrong>(b)(4)\u003C\u002Fstrong> piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\u003C\u002Fstrong> Specifically:\u003C\u002Fp>\u003Cp>A. Your procedure to define and document the schedule for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bowl and filter gauge pressure of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Machine “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (model # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, serial # \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is inadequate. The “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual requires drainage and monitoring of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> volume on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked \u003Cstrong>(b)(4)\u003C\u002Fstrong> and changed if it reaches \u003Cstrong>(b)(4)\u003C\u002Fstrong> PSI, there is no requirement to check the filter gauge pressure under the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” section of your maintenance log (or elsewhere).\u003C\u002Fp>\u003Cp>B. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, you plan to review the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeanne M. Phillips\n\nRecipient Title\n\nOwner and CEO\n\nPhillips Precision, Inc.\n\n7 Paul Kohner Pl\n\nElmwood Park, NJ 07407\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 697119\nDecember 9, 2024\nDear Ms. Jeanne M. Phillips:\nDuring an inspection of your firm located in Elmwood Park, NJ on April 22, 2024 through July 17, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm contract manufactures orthopedic implants and instruments. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Ms. Shalyn Creighton, Quality Assurance and Regulatory Compliance Manager, dated August 8, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you either failed to adequately implement or define and document requirements for your “Master Validation Plan Process and Software Validation” procedure (SOP-34; Rev. M and O; Effective: 6\u002F13\u002F14 and 5\u002F9\u002F19) which governed process validations for the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) and (b)(4) processes. For example:\nA. Cleaning validations conducted for the “(b)(4)” used to (b)(4) clean orthopedic implants and instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers, do not provide adequate assurance that the process consistently produces product that meets specifications. For example:\n1. You failed to adequately implement sections 5.3.7 and 5.3.9.3 of your process validation procedure (SOP-34; Rev. M) which required you to challenge your cleaning process under the worst-case product and process conditions during the operational qualification (OQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Operational Qualification (OQ) Protocol” (OQ_920-001; Rev. B; Approved 2\u002F5\u002F15), which includes the report. For example:\ni. Although your performance qualification (PQ) protocol required cytotoxicity, endotoxin, and particulate testing for the “(b)(4)” to demonstrate that cleanliness requirements were consistently met, you failed to conduct such testing during OQ which is defined in your procedure as “***documented verification that equipment performs in accordance with manufacturer’s specifications and process operating at [sic] the extremes of the equipment or process operating capabilities***.”\nii. You failed to adequately challenge the cleaning process under worst-case process parameters and product based on types and\u002For geometries, surface finishes, and processes conducted during OQ. For example, you did not challenge (b)(4) as all loads were run at (b)(4); system (b)(4) quality above (b)(4) microsiemens\u002F cm; clean time below (b)(4) minutes; and load weight above (b)(4) pounds. You also failed to define the worst-case setting for degassing time in the OQ protocol which your firm’s management stated is under (b)(4) minutes as well as document the degassing time during OQ.\nIn addition, you executed work orders during OQ without the (b)(4) manufacturing process, which your firm’s management identified during the inspection as a process that challenges your firm’s surface finishes and equipment process capabilities in (b)(4) out of (b)(4) work (WO #: 99343, 99284, 99336, and 98026-1) which were provided as worst case products.\nFurthermore, our investigator observed adhesive tape on the proximal femur left plasma implant (PF-2000L-02M; WO 102275) in the finishing department on 4\u002F26\u002F24. However, your OQ did not include challenges associated with the removal of adhesives and your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) does not establish cleaning specifications associated with this process.\niii. You failed to define or document the load configuration for work orders 65926 ((b)(4) devices), 64205 ((b)(4) devices), 63988 ((b)(4) devices), 65917 ((b)(4) devices), 65921 ((b)(4)75 devices), and 65791 ((b)(4) devices) in the OQ protocol and report in that your firm could not determine if devices were put in a single cleaning load or broken up into multiple (b)(4). In addition, you failed to challenge different loading configurations that your firm’s management stated are used during routine production such as the use of (b)(4) which is allowed in section 5.2.4.2.6 of your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) and (b)(4). On 4\u002F26\u002F24, our investigator observed the tibia stylus assembly instrument (Part # (b)(4); WO 101881) enclosed in a (b)(4) and the (b)(4) instrument (Part # (b)(4); WO 98151) placed on top of a (b)(4), neither of which were evaluated during OQ.\n2. You failed to adequately implement section 5.3.9.4 of process validation procedure (SOP-34; Rev. M) which required “***documented evidence that a process system performs as intended and that it demonstrates the capability to consistently meet appropriate specifications***” for the performance qualification (PQ) of your “(b)(4)” conducted under “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report. For example:\ni. As specified in section 5.2.2 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), you are to ensure that the system (b)(4) quality of the rinse tank is below (≤ (b)(4) microsiemens\u002Fcm) during normal operation of your (b)(4) cleaner. However, you failed to conduct PQ under normal operating conditions for system (b)(4) quality in that only (b)(4) out of (b)(4) runs were run at ≤ (b)(4) microsiemens\u002Fcm while the remaining cycles were run at (b)(4) and (b)(4) microsiemens\u002Fcm. In addition, you failed to define the optimal setting for degassing time in the PQ protocol as well as document the degassing time during execution of your PQ.\nii. You failed to utilize (b)(4) and (b)(4) which were sufficiently representative of manufactured devices. For example, WO # 99284 (Part # (b)(4)) includes surface finishes such as vibratory, deburring, and finishing and equipment processes such as (b)(4), assembly, machine, and (b)(4); however, these processes were not represented in the (b)(4) and (b)(4) utilized during your PQ and your firm did not document justification for the equivalency of those (b)(4) and (b)(4) through objective evidence.\n3. You failed to adequately implement section 5.1 of your process validation procedure (SOP-34; Rev. M) which requires a completed process failure modes and effects analysis (PFMEA) as a part of an approved validation plan and for which the definition under section 5.3.14 indicates that a PFMEA is used to “***assess quality risk levels to each step in a manufacturing process***” with a reference to your “Risk Management” procedure (SOP-35; Rev. K; Effective: 3\u002F9\u002F15) which outlines the criteria for severity scores on a scale of (b)(4) through (b)(4). For example, per section 10.4 of the “Final (b)(4) Cleaning Validation Plan” (VP_920_001; Rev. D; Effective: 3\u002F31\u002F15) for the “(b)(4)”, you utilized a PFMEA to assess quality risk levels that “***reflect[ed] the worst case process (for both clean and rinse) via processing***at maximum loading conditions (i.e. weight) for variable (b)(4) states @ (b)(4), (b)(4), and (b)(4)***.” However, you assigned a severity of (b)(4) ((b)(4)) out of (b)(4) for all but one of the failure modes for devices cleaned with your “Zenith” without determining if your firm was the final clean and if a severity score of 4 was appropriate. Your firm did not learn that it was the final clean for (b)(4) out of (b)(4) of your top customers until this information was requested during the inspection on 5\u002F2\u002F24. As of the close of the inspection, your firm had not evaluated the 8 other customers you have manufactured for since 2020 to determine if your firm is the final clean for them as well. For the 4 top customers for which your firm was the final cleaner, your firm manufactured and shipped (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); (b)(4) implants and (b)(4) instruments for Customer (b)(4); and (b)(4) instruments for Customer (b)(4).\nB. You failed to adequately implement 5.3.8 of your process validation procedure (SOP-34; Rev. O) which requires “***documented evidence providing high degree of assurance that a process***will consistently perform as intended” in that:\n1. You have not conducted a process validation for additional post-production final cleaning processes listed in the “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21), which allows for the use of (b)(4) and (b)(4), to provide adequate assurance that the process will consistently produce product that meet specifications. For example, on 4\u002F22\u002F24 and 4\u002F26\u002F24, our investigator observed your operators using (b)(4) and (b)(4) to wipe devices which had already been cleaned on the “(b)(4)”.\n2. The “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) only included devices composed of (b)(4) and (b)(4) stainless steel and did not include devices composed of titanium (which your firm’s management stated are also treated with (b)(4) during manufacturing) or documented justification for why validation of such devices was not necessary.\nC. You failed to adequately implement section 5.3.9.4 of your process validation procedure (SOP-34; Rev. M and O) which required “***documented evidence that a process system***demonstrates the capability to consistently meet appropriate specification***” and “***how\u002Fwhen samples will be taken, labeled, transported, and tested***” for the performance qualification (PQ) of your “(b)(4)”. For example:\n1. Your “Final (b)(4) Cleaning Process Qualification (PQ) Protocol” (PQ_920-001; Rev. B; Approved 3\u002F30\u002F15), which includes the report, for the “(b)(4)” did not utilize a sampling plan based on a valid statistical rationale for cytotoxicity, endotoxin, and particulate testing. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, the number of (b)(4) tested per lot for cytotoxicity and endotoxin was (b)(4) and (b)(4), respectively and the number of (b)(4) units tested for cytotoxicity, endotoxin, and particulate was (b)(4), and (b)(4), respectively. An AQL of (b)(4) for a sample size of (b)(4) and (b)(4) units per lot would have required testing on (b)(4) samples per lot for each test.\n2. Your “Validation Plan for (b)(4)” (VP_920-012; Rev. C; Effective: 6\u002F18\u002F19) did not utilize a sampling plan based on a valid statistical rationale. Although your “PPI Sampling Plan” procedure (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) requires you to use an AQL of (b)(4) unless otherwise specified, cytotoxicity testing was only conducted on (b)(4) out of (b)(4) per lot and endotoxicity and particulate testing was conducted on (b)(4) per lot. An AQL of (b)(4) would have required a sufficient number of samples to be able to test a minimum of (b)(4) samples each for endotoxins, cytotoxicity, and particulates for a lot size between (b)(4) and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the OQ for the “(b)(4)”, you plan to update the (b)(4) cleaning procedure and perform a revalidation which will challenge: the minimum and maximum critical process parameters with worst-case product and process (b)(4); removal of any adhesives; load configurations; comingling; multiple (b)(4); and (b)(4). However, there was no confirmatory statement that you plan to conduct cytotoxicity, endotoxin, and particulate testing during OQ or rationale for why this would not be necessary and explanation provided for use of worst-case product and process (b)(4) instead of actual products during OQ.\nWith regards to PQ for the “(b)(4)”, you dispute that (b)(4) purity of the rinse tank was not conducted at nominal; however, the (b)(4) and (b)(4) cycle was not done under normal operating conditions. You plan to update the (b)(4) cleaning procedure and perform a revalidation to include notation of the degassing time and use of worst-case product (b)(4). However, there was no corrective action identified to run system (b)(4) purity under normal operating conditions (≤ (b)(4) microsiemens\u002Fcm) and define the optimal degassing time.\nWith regards to the PFMEA for the “(b)(4)”, you intend to review and update the existing PFMEA as needed; contact (b)(4) of the (b)(4) customers you still do business with to determine whether your firm is the final clean and request their risk assessment; and do the same for any new customers in the future. However, there was no corrective action identified to proceduralized these actions. Furthermore, it is not clear whether you plan to update the respective severity scores for the process failure modes of the “(b)(4)”, for customer devices for which you are determined to be the final clean, in order to establish adequate quality risk levels.\nWith regards to (b)(4), you plan to “amend” the (b)(4) validation to include devices composed of titanium. However, it is unclear what the difference is between an amendment and a revalidation.\nWith regards to process validation for additional post-production cleaning processes, you state that the use of (b)(4), and (medical grade) (b)(4) to wipe post-production and post-final-cleaning is done in accordance with customer requirements. However, no supporting evidence was provided and rationale for why post-production final cleaning processes would be needed if the final cleaning process is meant to assure that cleaning requirements can consistently be met.\nWith regards to sampling, you plan to update the process validation procedure and ensure that the revalidation of the “(b)(4)” and amendment of the (b)(4) validation will utilize a statistically valid sampling plan based on documented rationale.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n2. Failure to establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications when deviations from device specifications could occur as a result of the manufacturing process, as required by 21 CFR 820.70(a).\nSpecifically, you failed to implement your “Final (b)(4) Cleaning ((b)(4))” (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21). For example:\nA. You failed to implement section 5.2.4.2.5 which states “(b)(4).” For example, on 4\u002F26\u002F24, our investigator observed comingling of the large (b)(4) instrument (Part # (b)(4); WO 101395) and (b)(4) instrument (Part # (b)(4); WO 99014) in the same (b)(4) load.\nB. You failed to implement section 5.2.4.2.1 which states “Do not stack product.” For example, on 4\u002F26\u002F24, our investigator observed two instances where devices were stacked upon each other within a cleaning load: (b)(4) release instrument (Part # (b)(4); WO 98145) and (b)(4) instrument (Part # (b)(4); WO 98151), which appeared be stacked in 3 layers. In addition, the “(b)(4)\" manual specifically states that “(b)(4).”\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to perform a revalidation on the “(b)(4)” to include challenges such as comingling and load configurations during OQ and review and update the PFMEA and (b)(4) cleaning procedure, as applicable. However, you have not provided any timelines for completion of any of your corrective actions and there was no corrective action identified to address that your employees were not following procedures. Furthermore, it is not clear how a revalidation on the “(b)(4)” that challenges comingling will address the original purpose which was to (b)(4), as noted in your (b)(4) cleaning procedure. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to adequately establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR 820.75(b). Specifically:\nA. You have not defined and documented procedures to monitor and control the following parameters for the validated (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) used to clean orthopedic implants and surgical instruments, for which your firm functions as the final cleaner for (b)(4) out of (b)(4) top customers:\n1. Weight of the Load (b)(4): There is no procedure to ensure that the load (b)(4) weight is below (b)(4) pounds, which was determined to be the limit during validation.\n2. Batch-to-Batch Temperature of the Cleaning Solution (i.e., Detergent) in the Clean and Rinse Tanks: There is no procedure to ensure that temperatures of the cleaning solution in the clean and rinse tanks between runs do not exceed the temperature limit of (b)(4)℉, which was determined to be the limit during validation.\n3. Concentration of the Cleaning Solution (i.e., Detergent): There is no procedure to ensure that the concentration of cleaning solution is monitored and controlled on a (b)(4) basis (with the use of a titration kit or other suitable means) to ensure adequate cleaning, which was specified during validation to be established per manufacturer’s instructions.\n4. Time for Degassing of Cleaning Solution (i.e., Detergent): There is no procedure to ensure that your “(b)(4)”, which operates at (b)(4)kHz, is degassed for (b)(4) to (b)(4) minutes before use for effective cavitation, which was specified during validation to be established per manufacturer’s instructions.\nB. You failed to implement sections 5.2.1.2 and 5.2.2.4 of your “Final (b)(4) Cleaning ((b)(4))” procedure (WI-920-001; Rev. K; Effective: 12\u002F10\u002F21) which requires verification of the temperature of the cleaning solution (i.e., detergent) in the clean and rinse tanks to ensure it is in the validated range of (b)(4)℉ to (b)(4)℉ and documentation of the temperature on the “(b)(4) Cleaning System Daily Temperature Log” (Form-03_01; Rev. F; Effective: 5\u002F25\u002F19) during startup of your “(b)(4)”. Overall, review of the temperature log from January 2, 2023 and March 26, 2024 revealed that approximately (b)(4)% ((b)(4) out of (b)(4)) of the loads run on your “(b)(4)” were performed at out of specification temperatures. For example, your employees operated your (b)(4) cleaner at temperatures lower than the minimum specified limit of (b)(4)℉ on 2\u002F28\u002F23; 4\u002F6\u002F23; 4\u002F25\u002F23; 5\u002F19\u002F23; 5\u002F20\u002F23; 5\u002F22\u002F23; 5\u002F24\u002F23; and 7\u002F1\u002F23, implicating at least (b)(4) orthopedic devices ((b)(4) implants and (b)(4) surgical instruments).\nC. You have not established a procedure for the monitoring and control of temperature and time for (b)(4). Section 6.2 of your “(b)(4)” procedure (WI-920-005; Rev. F; Effective: 9\u002F6\u002F17) states that the “***(b)(4) is pre-heated***between (b)(4) and (b)(4) F for a minimum of (b)(4) prior to application.”\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to the inadequate monitoring and control of the above parameters, you plan to reevaluate monitoring and controls after revalidation of the “(b)(4)”; update the frequency as needed; and revise the (b)(4) cleaning procedure to establish the applicable batch-to-batch temperature for the tanks.\nWith regards to out of specification temperature recordings, you explain the temperatures would have increased as the morning went on such that only the first one or two runs of each day would have been affected; your employee may have misunderstood the process and either was not fully aware of the minimum temperature and\u002For what to do in the event the temperature was below the limit; and that because the minimum temperature proposed in the user manual is (b)(4)℉ and that the (b)(4) cleaning action only begins to deteriorate when temperatures go above certain limits (typically (b)(4)℉), the risk of impact to the parts cleaned on the specified days is low. However, there were temperatures noted above the validated temperature range of (b)(4)℉ on 8\u002F18\u002F23; 10\u002F10\u002F23; 1\u002F15\u002F24; 2\u002F1\u002F24; and 4\u002F1\u002F24. Additional temperatures below (b)(4)℉ were also noted on 8\u002F7\u002F23; 8\u002F12\u002F23; 8\u002F24\u002F23; and 11\u002F3\u002F23.\nYou also plan to update the (b)(4) cleaning procedure to include an explanation of what to do in the event the temperature is below the minimum temperature; train applicable employees as well as to the nonconforming product procedure to identify nonconformances regarding parts themselves; and update the PFMEA to include the risks associated with parts processed outside of the specified temperature limits. However, there were no corrective actions identified to (1) address that your employees were not following procedures to ensure that the startup temperatures were within specified limits and (2) update the (b)(4) cleaning procedure to specify how long employees should wait before measuring the temperature for verification before use of the (b)(4) cleaner.\nWith regards to the inadequate monitoring and control of parameters for (b)(4), you plan to review the (b)(4) validation and establish the applicable monitoring and control and amend the (b)(4) procedure to these said controls.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n4. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically:\nA. You either failed to define and document requirements in your Corrective\u002F Preventive Action Process” procedure (SOP-29, Rev. F, Effective: 10\u002F19\u002F18) or adequately implement sections 5.3, 5.4, and 5.5 which require a “***comprehensive and thorough***” root cause analysis, identification “***of all the actions to prevent recurrence***,” and verification “***that the issue has in fact gone away or been reduced***,” respectively, as required by 21 CFR 820.100(a)(2), 820.100(a)(3), and 820.100(a)(4). For example:\n1. Your corrective and preventative action (CAPA) procedure is inadequate in that it does not define or document the requirement to verify or validate corrective actions prior to implementation to ensure they are effective. For CAPA 1175 opened on 11\u002F30\u002F23 for (b)(4) blades received with metal debris, leftover burrs, and residue corresponding to (b)(4) devices (Part # (b)(4)), the corrective actions included (1) increasing clean time to (b)(4) minutes for your in-process (b)(4) cleaning machines; (2) verifying use of the custom (b)(4) fixture; and (3) utilizing additional inspectional tools with both magnification and lighting. However, you did not perform verification or validation activities prior to implementation of the corrective actions to ensure they would be able to remove residue.\n2. For CAPA 1175, you failed to adequately implement section 5.3 of your CAPA procedure because your investigation did not include an assessment on whether the residue, caused by improper placement of the devices in the in-process (b)(4) machines, may have affected other devices with similar geometries which also use the in-process (b)(4) machines to remove residue and metal shards.\n3. For CAPA 1166 opened on 7\u002F11\u002F22 to address “staining and contaminants on the (b)(4)” on at least (b)(4) devices (Part # (b)(4)) you contract manufactured under 30 work orders between 1\u002F7\u002F19 to 8\u002F22\u002F22, you failed to implement sections 5.3, 5.4, and 5.5 of your CAPA procedure: (1) investigate the specific causes behind the different types of stains (light stain, glue\u002Ftransfer, oxidation, dark stain, and material transfer); (2) provide objective evidence that return material authorizations (RMAs) for (b)(4) lines were monitored from 3\u002F10\u002F23 to 3\u002F17\u002F23 per the verification plan; and (3) prevent recurrence of this issue in that from 3\u002F17\u002F23 to 4\u002F1\u002F24, you received 7 additional customer complaints\u002Fexternal NCMs (3893; 3902; 3946; 3947; 3980; 3982; and 3984) for stains on at least 7 of the same part numbers ((b)(4)) processed under 7 different work orders that were shipped after implementation of the corrective action on 3\u002F10\u002F23.\nB. Your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Eff. 6\u002F28\u002F22), which includes criteria for when corrective and preventive actions (CAPAs) should be initiated, is inadequate in that it does not define and document requirements for analyzing quality data (e.g., complaints, nonconformances, processes, returns, CAPAs, etc.) to identify existing and potential causes of nonconforming product, or other quality problems, using appropriate statistical methodology where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example:\n1. Section 6.0 outlines the threshold for when a CAPA should be initiated for a nonconformance report. Threshold categories include Critical to Quality (Score: (b)(4)); Rejection % (Score: (b)(4)); Occurrence (Score (b)(4)); and Detectability ((b)(4)). A combined score of (b)(4) or above requires initiation of a CAPA. However, your “Detectability” rating does not associate lower ability to detect a nonconformity with a higher risk as a score of (b)(4) is defined as “Almost Certain” while a score of (b)(4) is defined as “Low to Almost Impossible.” Under this scoring system, recurring quality problems may not be detected because a CAPA would not be initiated for cases where detection was low to almost impossible.\n2. Section 5.8.3 states “***the QC Operations Manager***shall review nonconformance data***and determine if trends [for scrapped items, reworked product, nonconforming materials (NCMs)] or significant issue are identifiable and corrective action is warranted***” and that NCM\u002FCAPA meetings will be held periodically to discuss the status of open NCM\u002FCAPAs, trends, and NCM history. However, the procedure does not define and document how you are to analyze internal and external nonconformances as well as other quality data sources (e.g., (b)(4) data) to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology.\n3. Your nonconformance procedure does not define and document requirements to analyze nonconformances generated from a process that may encompass various part numbers in that your firm’s management stated you only trend nonconformance types by part number. During the inspection, analysis of nonconformances associated with stains between 1\u002F1\u002F20 to 4\u002F1\u002F24 by part number failed to detect a notable trend. When the same data set was analyzed across part numbers, there were 48 nonconformances associated with stains across (b)(4) unique part numbers.\n4. Your nonconformance procedure does not define and document the nonconformance types (e.g., Major, Manufacturing, GMP, Functional, Dimensional, Gauge etc.), used to categorize nonconformances, to ensure nonconforming product will be consistently assigned a NCM (nonconforming material) type to allow for accurate analysis of this data to identify existing and potential causes of nonconforming product, or other quality problems. For example, NCM # 3458 and NCM # 3469 represent nonconformances associated with devices failing no-go gauges. Employee (b)(4) categorized NCM # 3458 as “Dimensional” and the same employee characterized NCM # 3469 as “Guage.” These nonconformances referenced different work orders; however, they each contained identical descriptions, dispositions, and verifications which are specific to the same dimension and no-go gauge.\nWe reviewed your firm’s response and conclude that it is not adequate.\nWith regards to CAPA 1175, you plan to investigate the feasibility of the process improvement determined from this CAPA on other product lines. However, there were no corrective actions identified to update your CAPA procedure to include verification or validation of corrective actions prior to implementation.\nWith regards to CAPA 1166, you explain that staining occurred after product left your firm because you were unable to replicate some of the observed staining; you implemented a 100% visual inspection prior to packaging and shipment and plan to document the visual inspection records for the multiples (b)(4) orders verified from 3\u002F10\u002F23 to 3\u002F17\u002F23 as evidence; and you monitored RMAs requests across products lines for (b)(4) associated with staining, marks, and contamination from 3\u002F10\u002F23 to 3\u002F17\u002F23 as required by your verification plan. However, none of these conclusions, details, or activities were documented or referenced in your CAPA as part of the investigation, corrective action, and\u002For verification activities. Overall, there were no corrective actions identified to address the failure to include objective evidence of verification; incomplete documentation of the full investigation, identified corrective actions, and verification plan; and observed recurrence of the issue.\nWith regards to data analysis, you state you intend to define a final internal nonconforming material (NCM) tracking and trending process within a procedure. However, there were no corrective actions identified to revise the detectability score to ensure that the lowest detectability level equates to the highest score (b)(4) not lowest score (b)(4) and retrospectively review NCMs, for a reasonable period of time, to update CAPA threshold scores to determine whether any CAPAs should have been initiated.\nWith regards to categorization of nonconformances, you plan to review and update the existing NCM types listed within the system (as needed); define NCM types; and add instructions on how to correct NCM types after initial entry. However, there were no corrective actions identified to retrospectively review NCM types for accuracy, for a reasonable period of time, to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review.\nYou have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22) (nor any other procedure) is inadequate in that there is no requirement to identify, document, and evaluate the following internal nonconformances to determine the need for an investigation. For example:\nA. Internal Nonconformances, found during manufacturing and inspections (excluding (b)(4) inspections – Per your undocumented process, a supervisor logs parts that are out of specification (OOS) into the (b)(4) software application and informs your Quality Control (QC) Operations Manager, who in turn enters it on the “Internal NO NCM Issues” log and decides whether to open an official NCM report requiring an investigation per the nonconforming product procedure.\nB. Internal nonconformances, only found during (b)(4) inspections conducted during manufacturing – Per your undocumented process, your QC Operations Manager evaluates the part, approves the disposition of scrap on the inspection guide sheet (IGS), documents it on the “NCM Internal (b)(4) Scrap Log” and then discards the part along with the (b)(4) report containing the OOS measurement. In turn, your operator enters the scrap on the IGS and (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. There were no actions identified to define and document how internal nonconformances will be evaluated to determine the need for an investigation. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to establish and maintain procedures for acceptance activities, including inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\nSpecifically, you failed to implement section 6.1.6.1(o) of your “Inspection Process” procedure (SOP-54; Rev. L; Effective: 3\u002F17\u002F23) which states the supervisor (or designate) “***must adhere to the Inspection Frequency as written. If the Inspection Frequency is at an AQL level, the Inspection Frequency is derived from DOC-03 PPI Sampling Plan***.” DOC-3 further references “(b)(4) Acceptance Number Sampling Plan Fifth Edition” which requires (b)(4) sampling. For example:\nA. During in-process inspection of the small spacer intended for implantation during shoulder surgery (Part # (b)(4)), your personnel only used your (b)(4) to measure the critical diameter feature (b)(4) times (to include (b)(4)). Per your inspection guide sheet (IGS) for this part, the feature was required to be measured (b)(4) times at (b)(4) since the inspection plan was specified to follow the Acceptable Quality Limit of (b)(4) (AQL (b)(4)) defined in “PPI Sampling Plan” (DOC-03; Rev. E; Effective: 12\u002F10\u002F14) for lot sizes of (b)(4) and (b)(4) under the respective Work Orders (WO) 86995 and 99431, respectively. For WO # 86995, you received a complaint\u002Fexternal nonconformance (NCM # 3287\u002FCAPA 1122) which resulted in (b)(4) devices being returned and scrapped due to diameters exceeding the specified limit of (b)(4) +\u002F- (b)(4).\nB. On 5\u002F17\u002F24, our investigator observed employee (b)(4) operate the (b)(4) for machining of the metal locking date ring (Part # (b)(4)) under WO # 102106. Your operator explained that every (b)(4) piece is inspected using a caliper. However, the in-process router states that this operation requires a 100% inspection.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to revise the IGS to include column headers and an explanation to record the data for the first setup piece, middle piece, and last piece; review and update the inspection process procedure with the above changes; and provide training on these requirements with an emphasis for operators to follow the specified (b)(4) frequency. However, there were no actions identified to determine to determine the pervasiveness of the issue to guide further corrective action(s) based on the results of the review. Furthermore, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n7. Failure to adequately establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1). Specifically:\nA. Your procedure to define and document the schedule for the (b)(4) bowl and filter gauge pressure of the (b)(4) Cleaning Machine “(b)(4)” (model # (b)(4), serial # (b)(4)) is inadequate. The “(b)(4)” manual requires drainage and monitoring of the (b)(4) volume on a (b)(4) basis to prevent liquid from dripping on internal machine components. However, your firm only conducts and documents this maintenance (b)(4) on the (b)(4) Cleaning System Maintenance Log (Form-03). In addition, although the manual states that the filter gauge pressure should be checked (b)(4) and changed if it reaches (b)(4) PSI, there is no requirement to check the filter gauge pressure under the “(b)(4)” section of your maintenance log (or elsewhere).\nB. You do not define, document, and maintain schedules for the adjustment and maintenance of tooling to ensure manufacturing specifications are met. For example, on 4\u002F26\u002F24, our investigator observed an instance where your (b)(4) machine was operating with a 0% tool life during the manufacturing of Work Order 101053-1. Per your firm’s management, tool changes may be considered when the machinist deems it necessary based on associated feature measurements, visual checks for a nonconformity on the surface finish of the part, or changes in the tool sound while engaged in the cut. In addition, the machinist may make an adjustment in the tool data page to compensate for the tool wear.\nWe reviewed your firm’s response and conclude that it is not adequate. As a part of the revalidation of the “(b)(4)”, you plan to review the “(b)(4)” manual and compare it with the existing preventive maintenance form and update the frequency as needed, and if you determine that a frequency different from what the manual dictates is acceptable, a risk assessment will be performed and documented. You also state that the tooling observation is under review while you consider the best course of action. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n8. Failure to adequately establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\nSpecifically, operators who conduct machining of raw materials, assembly, and finishing have not been trained on your “Control of Nonconforming Product” procedure (SOP-33; Rev. P; Effective: 6\u002F28\u002F22). For example, review of 11 training records revealed (b)(4) operators who have not been trained in this procedure. These individuals perform in-process inspections and have the ability to reject and accept devices.\nWe reviewed your firm’s response and conclude that it is not adequate. You plan to update your nonconforming product procedure to include a section for all operators, finishers, and inspectors to state what should be done in the event nonconforming product is found during manufacturing and train all applicable employees to this updated procedure. However, you have not provided any timelines for completion of any of your corrective actions. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review and timelines for completion.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS Case # 697119 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Phillips Precision, Inc.","phillips-precision-inc-697119-12092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fphillips-precision-inc-697119-12092024","2026-10-26T08:09:41.686932+00:00","2025-01-14","697119","Medical Devices","Jeanne M. Phillips","2026-08-19T17:04:56.275+00:00","VIA Electronic Mail","2024-12-09",{"id":136,"raw":137,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":149,"fei_number":20,"letter_url":150,"updated_at":151,"action_type":23,"case_status":152,"posted_date":153,"marcs_cms_no":154,"product_type":108,"closeout_date":155,"issuing_office":141,"recipient_name":156,"body_fetched_at":157,"delivery_method":133,"recipient_title":20,"reference_number":20,"action_taken_date":158,"medical_device_id":20,"response_letter_date":20},3285,[138,139,140,141,142,13,143,13],"\u003Ctime datetime=\"2021-06-29T13:20:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-23T04:00:00Z\">06\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-healthworks-inc-611686-06232021\">Great Healthworks, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations, Division IV East","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-healthworks-inc-611686-01252022\">\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ken Meares\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Healthworks, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4150 SW 28th Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33312-5201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations, Division IV East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 23, 2021\u003C\u002Fp>\n\n\u003Cp>21-HAFE4-WL-06\u002FCMS No. 611686\u003Cbr>\n\u003Cbr>\nDear Mr. Meares:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.greathealthworks.com\u002F in May 2021 and has determined that you take orders there for the products ProbioticXL and OmegaXL. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Further, even if your ProbitoticXL were not an unapproved new drug, it would be a misbranded food under section 403 of the Act [21 U.S.C. 343]. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>ProbioticXL\u003C\u002Fp>\n\n\u003Cp>On the webpage https:\u002F\u002Fprobioticxl.com\u003C\u002Fp>\n\n\u003Cp>• “Combats bad bacteria”\u003Cbr>\n• “ ClearPhage® [an ingredient in PriobioticXL] is a natural patented ingredient that targets harmful bacteria . . ..”\u003C\u002Fp>\n\n\u003Cp>On your website page: https:\u002F\u002Fprobioticxl.com\u002Fprobiotics-and-your-health\u002F\u003Cbr>\n• “ProbioticXL® reduces harmful bacteria with its prebiotic – ClearPhage™.”\u003Cbr>\n• “ProbioticXL® . . . inhibits yeast growth with its Protective Shield Technology.”\u003C\u002Fp>\n\n\u003Cp>On your website page https:\u002F\u002Fprobioticxl.com\u002Fwhy-probioticxl\u002F\u003Cbr>\n• “Reduces harmful bacteria with its prebiotic – ClearPhage™”\u003Cbr>\n• “Protective Shield Technology – . . . reduces potentially harmful bacteria. Inhibits yeast growth . . .”\u003Cbr>\n• “ClearPhage™ [an ingredient in ProbioticXL®] – Reduces harmful bacteria”\u003Cbr>\n• “Reduce abdominal pain . . .”\u003Cbr>\n• “Reduce the risk factors of cardiovascular disease, especially in smokers”\u003Cbr>\n• “Calm skin irritation”\u003Cbr>\n• “Protect the intestinal barrier against damage . . .”\u003Cbr>\n• “Sustain normal levels of intestinal bacteria post-antibiotic treatment”\u003Cbr>\n• “Alleviate inflammation in the large intestine”\u003Cbr>\n• “Reduce cardiovascular disease risk factors . . .”\u003Cbr>\n• “[C]learPhage™ is a natural patent pending ingredient that inhibits the growth of harmful bacteria . . ..”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fprobioticxl.com\u002Fthe-science-behind-probioticxl\u002F\u003Cbr>\n• “Reduce harmful bacteria in the intestine”\u003Cbr>\n• “Inhibit yeast growth”\u003Cbr>\n• “Lactobacillus Acidophilus [an ingredient in ProbioticXL®] = Reduces abdominal pain”\u003Cbr>\n• “Lactobacillus Plantarum [an ingredient in ProbioticXL®] = Reduces the risk factors of cardiovascular disease, especially in smokers”\u003Cbr>\n• “Lactobacillus Rhamnosus [an ingredient in ProbioticXL®] = Calms skin irritation”\u003Cbr>\n• “Lactobacillus Salivarius [an ingredient in ProbioticXL®] = Protects the intestinal barrier against damage”\u003Cbr>\n• “Lactobacillus Brevis[an ingredient in ProbioticXL®] = Improves inflamed gum conditions”\u003Cbr>\n• “Bifidobacterium Lactis [an ingredient in ProbioticXL®] = Sustains normal levels of intestinal bacteria post antibiotic treatment”\u003Cbr>\n• “Bifidobacterium Bifidum [an ingredient in ProbioticXL®] = Alleviates inflammation in the large intestine”\u003Cbr>\n• “Streptococcus Thermophilus [an ingredient in ProbioticXL®] = Reduces cardiovascular disease risk factors . . .”\u003C\u002Fp>\n\n\u003Cp>OmegaXL\u003C\u002Fp>\n\n\u003Cp>On your webpage: https:\u002F\u002Fwww.greathealthworks.com\u002F\u003Cbr>\n• “[S]hown to help relieve joint pain due to inflammation”\u003Cbr>\n• “OmegaXL is widely recognized as a leader in natural relief from pain due to inflammation.”\u003Cbr>\n\u003Cbr>\nOn the webpage: https:\u002F\u002Fwww.omegaxl.com\u002F\u003Cbr>\n• “In a study of 50 participants, the group taking the active ingredient in Omega XL, the lipid extract from the New Zealand Green-Lipped Mussel, showed an 89% improvement in joint discomfort due to inflammation.”\u003C\u002Fp>\n\n\u003Cp>OmegaXL order form page:\u003Cbr>\n• “Helps reduce joint pain due to inflammation”\u003C\u002Fp>\n\n\u003Cp>On your product page under OmegaXL Blog: Blog post “What Makes OmegaXL So Effective? PCSO-524” dated May 15, 2014:\u003Cbr>\n• “(PCSO-524), found in OmegaXL, has demonstrated to be an effective complementary or alternative course of action for providing relief from joint pain, as well as other inflammatory conditions . . . OmegaXL gel caps have been sold to satisfied customers who enthusiastically confirm the incredible inflammation fighting and long term joint pain managing effect they experienced with this unique, all-natural product.”\u003C\u002Fp>\n\n\u003Cp>On your product page under “Joint Discomfort”:\u003Cbr>\n• “[O]MEGAXL HELPS RELIEVE JOINT DISCOMFORT ON MANY LEVELS . . . Joint discomfort due to inflammation hurts . . .”\u003Cbr>\n• “OmegaXL is shown in clinical research to help relieve joint discomfort due to inflammation.”\u003C\u002Fp>\n\n\u003Cp>On your product page under “Why OmegaXL”:\u003Cbr>\n• “[D]emonstrated in over 30 years of clinical research to help relieve joint discomfort due to inflammation . . .”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Food\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your ProbioticXL product was not an unapproved new drug, it would be a misbranded food within the meaning of section 403(r)(1)(B) of the Act [21 U.S.C.343(r)(1)(B)] in that the product labeling bears the following unauthorized health claims:\u003C\u002Fp>\n\n\u003Cp>• On your website https:\u002F\u002Fprobioticxl.com\u002Fwhy-probioticxl\u002F:\u003Cbr>\no “Reduce the risk factors of cardiovascular disease, especially in smokers”\u003Cbr>\no “Reduce cardiovascular disease risk factors together with Lactobacillus Rhamnosus and Lactobacillus Acidophilus”\u003C\u002Fp>\n\n\u003Cp>• On your website https:\u002F\u002Fprobioticxl.com\u002Fthe-science-behind-probioticxl\u002F:\u003Cbr>\no “Lactobacillus Plantarum [an ingredient in ProbioticXL®] = Reduces the risk factors of cardiovascular disease, especially in smokers”\u003Cbr>\no “Streptococcus Thermophilus [an ingredient in ProbioticXL®] = Reduces cardiovascular disease risk factors together with Lactobacillus Rhamnosus and Lactobacillus Acidophilus.”\u003C\u002Fp>\n\n\u003Cp>These health claims misbrand your product because they have not been authorized either by regulation [see section 343(r)(3)(A)-(B) of the Act [21 U.S.C. § 343(r)(3)(A)(B)]] or under authority of the health claim notification provision of the Act [see section 343(r)(3)(C) of the Act [21 U.S.C. § 343(r)(3)(C)]]. We also note that FDA has not issued a Letter of Enforcement Discretion for such claims.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to the Food and Drug Administration, Attention to: Mr. Ramon Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact Ms. Beira Montalvo, Compliance Officer, at (561) 416-1065 ext. 1108 or via e-mail at Beira.Montalvo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDirector, San Juan District Office\u003Cbr>\nProgram Division Director,\u003Cbr>\nOffice of Human and Animal Food Operations,\u003Cbr>\nDivision IV East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Ken Meares\n\nRecipient Title\n\nChief Executive Officer\n\nGreat Healthworks, Inc.\n\n4150 SW 28th Way\n\nFort Lauderdale, FL 33312-5201\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations, Division IV East\n\nUnited States\n\nWARNING LETTER\n\nJune 23, 2021\n\n21-HAFE4-WL-06\u002FCMS No. 611686\n\nDear Mr. Meares:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.greathealthworks.com\u002F in May 2021 and has determined that you take orders there for the products ProbioticXL and OmegaXL. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Further, even if your ProbitoticXL were not an unapproved new drug, it would be a misbranded food under section 403 of the Act [21 U.S.C. 343]. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nProbioticXL\n\nOn the webpage https:\u002F\u002Fprobioticxl.com\n\n• “Combats bad bacteria”\n\n• “ ClearPhage® [an ingredient in PriobioticXL] is a natural patented ingredient that targets harmful bacteria . . ..”\n\nOn your website page: https:\u002F\u002Fprobioticxl.com\u002Fprobiotics-and-your-health\u002F\n\n• “ProbioticXL® reduces harmful bacteria with its prebiotic – ClearPhage™.”\n\n• “ProbioticXL® . . . inhibits yeast growth with its Protective Shield Technology.”\n\nOn your website page https:\u002F\u002Fprobioticxl.com\u002Fwhy-probioticxl\u002F\n\n• “Reduces harmful bacteria with its prebiotic – ClearPhage™”\n\n• “Protective Shield Technology – . . . reduces potentially harmful bacteria. Inhibits yeast growth . . .”\n\n• “ClearPhage™ [an ingredient in ProbioticXL®] – Reduces harmful bacteria”\n\n• “Reduce abdominal pain . . .”\n\n• “Reduce the risk factors of cardiovascular disease, especially in smokers”\n\n• “Calm skin irritation”\n\n• “Protect the intestinal barrier against damage . . .”\n\n• “Sustain normal levels of intestinal bacteria post-antibiotic treatment”\n\n• “Alleviate inflammation in the large intestine”\n\n• “Reduce cardiovascular disease risk factors . . .”\n\n• “[C]learPhage™ is a natural patent pending ingredient that inhibits the growth of harmful bacteria . . ..”\n\nOn your webpage https:\u002F\u002Fprobioticxl.com\u002Fthe-science-behind-probioticxl\u002F\n\n• “Reduce harmful bacteria in the intestine”\n\n• “Inhibit yeast growth”\n\n• “Lactobacillus Acidophilus [an ingredient in ProbioticXL®] = Reduces abdominal pain”\n\n• “Lactobacillus Plantarum [an ingredient in ProbioticXL®] = Reduces the risk factors of cardiovascular disease, especially in smokers”\n\n• “Lactobacillus Rhamnosus [an ingredient in ProbioticXL®] = Calms skin irritation”\n\n• “Lactobacillus Salivarius [an ingredient in ProbioticXL®] = Protects the intestinal barrier against damage”\n\n• “Lactobacillus Brevis[an ingredient in ProbioticXL®] = Improves inflamed gum conditions”\n\n• “Bifidobacterium Lactis [an ingredient in ProbioticXL®] = Sustains normal levels of intestinal bacteria post antibiotic treatment”\n\n• “Bifidobacterium Bifidum [an ingredient in ProbioticXL®] = Alleviates inflammation in the large intestine”\n\n• “Streptococcus Thermophilus [an ingredient in ProbioticXL®] = Reduces cardiovascular disease risk factors . . .”\n\nOmegaXL\n\nOn your webpage: https:\u002F\u002Fwww.greathealthworks.com\u002F\n\n• “[S]hown to help relieve joint pain due to inflammation”\n\n• “OmegaXL is widely recognized as a leader in natural relief from pain due to inflammation.”\n\nOn the webpage: https:\u002F\u002Fwww.omegaxl.com\u002F\n\n• “In a study of 50 participants, the group taking the active ingredient in Omega XL, the lipid extract from the New Zealand Green-Lipped Mussel, showed an 89% improvement in joint discomfort due to inflammation.”\n\nOmegaXL order form page:\n\n• “Helps reduce joint pain due to inflammation”\n\nOn your product page under OmegaXL Blog: Blog post “What Makes OmegaXL So Effective? PCSO-524” dated May 15, 2014:\n\n• “(PCSO-524), found in OmegaXL, has demonstrated to be an effective complementary or alternative course of action for providing relief from joint pain, as well as other inflammatory conditions . . . OmegaXL gel caps have been sold to satisfied customers who enthusiastically confirm the incredible inflammation fighting and long term joint pain managing effect they experienced with this unique, all-natural product.”\n\nOn your product page under “Joint Discomfort”:\n\n• “[O]MEGAXL HELPS RELIEVE JOINT DISCOMFORT ON MANY LEVELS . . . Joint discomfort due to inflammation hurts . . .”\n\n• “OmegaXL is shown in clinical research to help relieve joint discomfort due to inflammation.”\n\nOn your product page under “Why OmegaXL”:\n\n• “[D]emonstrated in over 30 years of clinical research to help relieve joint discomfort due to inflammation . . .”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nMisbranded Food\n\nEven if your ProbioticXL product was not an unapproved new drug, it would be a misbranded food within the meaning of section 403(r)(1)(B) of the Act [21 U.S.C.343(r)(1)(B)] in that the product labeling bears the following unauthorized health claims:\n\n• On your website https:\u002F\u002Fprobioticxl.com\u002Fwhy-probioticxl\u002F:\n\no “Reduce the risk factors of cardiovascular disease, especially in smokers”\n\no “Reduce cardiovascular disease risk factors together with Lactobacillus Rhamnosus and Lactobacillus Acidophilus”\n\n• On your website https:\u002F\u002Fprobioticxl.com\u002Fthe-science-behind-probioticxl\u002F:\n\no “Lactobacillus Plantarum [an ingredient in ProbioticXL®] = Reduces the risk factors of cardiovascular disease, especially in smokers”\n\no “Streptococcus Thermophilus [an ingredient in ProbioticXL®] = Reduces cardiovascular disease risk factors together with Lactobacillus Rhamnosus and Lactobacillus Acidophilus.”\n\nThese health claims misbrand your product because they have not been authorized either by regulation [see section 343(r)(3)(A)-(B) of the Act [21 U.S.C. § 343(r)(3)(A)(B)]] or under authority of the health claim notification provision of the Act [see section 343(r)(3)(C) of the Act [21 U.S.C. § 343(r)(3)(C)]]. We also note that FDA has not issued a Letter of Enforcement Discretion for such claims.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to the Food and Drug Administration, Attention to: Mr. Ramon Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact Ms. Beira Montalvo, Compliance Officer, at (561) 416-1065 ext. 1108 or via e-mail at Beira.Montalvo@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDirector, San Juan District Office\n\nProgram Division Director,\n\nOffice of Human and Animal Food Operations,\n\nDivision IV East","Great Healthworks, Inc.","great-healthworks-inc-611686-06232021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-healthworks-inc-611686-06232021","2026-10-26T08:08:49.415759+00:00","Closed Out","2021-06-29","611686","2022-02-02","Mr. Ken Meares","2026-08-20T03:02:41.64+00:00","2021-06-23",{"id":160,"raw":161,"subject":166,"body_html":168,"body_text":169,"firm_name":170,"letter_id":171,"created_at":149,"fei_number":20,"letter_url":172,"updated_at":173,"action_type":23,"case_status":152,"posted_date":174,"marcs_cms_no":175,"product_type":176,"closeout_date":177,"issuing_office":165,"recipient_name":178,"body_fetched_at":179,"delivery_method":180,"recipient_title":20,"reference_number":20,"action_taken_date":181,"medical_device_id":20,"response_letter_date":20},3339,[162,163,164,165,166,13,167,13],"\u003Ctime datetime=\"2021-05-25T13:20:00Z\">05\u002F25\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-10T04:00:00Z\">05\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-lakes-gelatin-company-612323-05102021\">Great Lakes Gelatin Company\u003C\u002Fa>","Office of Human and Animal Food Operations East-VI","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-lakes-gelatin-company-612323-11052021\">\u003Ctime datetime=\"2021-11-05T04:00:00Z\">11\u002F05\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Certified Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Burkett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Lakes Gelatin Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>253 Commerce Dr., Ste 101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grayslake\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60030\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East-VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY21-HAFE6-WL-03\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 10, 2021\u003C\u002Fp>\n\n\u003Cp>Re: 612323\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Burkett:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.greatlakesgelatin.com in March – May 2021, and has determined that you take orders there for the products Collagen Hydrolysate (10 oz unflavored and vanilla, mixed berry, lemon + lime, apple + cucumber, chocolate, and chai flavors, 16 oz unflavored, Convenience Pack (20 count unflavored), 8lb unflavored), Keto Collagen + MCT, and Collagen Endurance Plus. We have also reviewed your social media websites at www.facebook.com\u002Fgreatlakesgel\u002F and http:\u002F\u002Fwww.pinterest.com\u002Fgreatlakesgel\u002F, which direct consumers to your website www.greatlakesgelatin.com, where you take orders for your products. In addition, your website www.greatlakesgelatin.com links to your YouTube channel https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUClCQa2KGaAVEw_ROlp-dCAQ. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products (which, as indicated on your website, contain collagen hydrolysate (also referred to as hydrolyzed collagen))\u003C\u002Fp>\n\n\u003Cp>On your website www.greatlakesgelatin.com:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the “About Great Lakes Gelatin” webpage of your website:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“We pioneered the ‘original’ Collagen Hydrolysate, and this amazing product has helped thousands of people see the benefits of . . . reduced joint pain . . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the “Why Collagen” webpage of your website:\u003C\u002Fstrong>\u003Cbr>\nArtwork with pop-up text - “Natural, Anti Inflammatory”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the “Healthy Living” webpage of your website:\u003C\u002Fstrong>\u003Cbr>\n“Many of our customers also report that their joint pain or discomfort has eased . . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the “FAQS” webpage of your website:\u003C\u002Fstrong>\u003Cbr>\n“What are the benefits of collagen and gelatin? . . . Reduces joint pain”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “COLLAGEN SUPPLEMENTATION AND GASTROINTESTINAL HEALTH” on your website:\u003C\u002Fstrong>\u003Cbr>\n“Many of the amino acids in collagen protect the gastrointestinal tract by regulating stomach acid secretions, preventing stomach ulcers, helping to heal gastrointestinal lining, reducing and preventing inflammation of the GI tract . . . .”\u003C\u002Fp>\n\n\u003Cp>“One research study attempting to promote mucosal healing in ulcerative colitis found that by day 13 of supplementing with collagen hydrolysate rectal bleeding completely stopped.”\u003C\u002Fp>\n\n\u003Cp>“In the same study, there was also evidence found that collagen hydrolysate provided an anti-inflammatory effect as well as protection to the intestinal mucosa . . . .”\u003C\u002Fp>\n\n\u003Cp>“Many who suffer from leaky gut syndrome use collagen hydrolysate as a supplement to aid in symptom management as well.”\u003C\u002Fp>\n\n\u003Cp>“The amino acids glutamine, glycine lysine, serine, and threonine found in collagen hydrolysate all help . . . . Glycine . . . may protect against stomach ulcers by minimizing unnecessary stomach acid secretion.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “COLLAGEN SUPPLEMENTATION AND BONE AND JOINT HEALTH” on your website:\u003C\u002Fstrong>\u003Cbr>\n“Collagen may help to:… reduce joint pain … and aid in repair of broken bones.”\u003C\u002Fp>\n\n\u003Cp>“Collagen has a therapeutic role in the prevention and treatment of osteoporosis and osteoarthritis; including increased osteoblast proliferation, mineralized bone matrix formation, bone preservation and increased bone mineral density.”\u003C\u002Fp>\n\n\u003Cp>“Collagen has also been shown to stimulate bone forming cells, protecting against excessive bone loss . . . .”\u003C\u002Fp>\n\n\u003Cp>“Several of the amino acids in collagen . . . . Glycine may help to protect against arthritis and histidine can be used to treat rheumatoid arthritis. . . . Phenylalanine helps to reduce arthritic pain.”\u003C\u002Fp>\n\n\u003Cp>“To summarize, supplementing with collagen may help to reduce pain from osteoarthritis, increase bone mineral density, decrease joint pain . . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “WHY CHOCOLATE HEARTS AREN'T THE ONLY HEART YOU SHOULD BE FOCUSED ON THIS FEBRUARY” on your website:\u003C\u002Fstrong>\u003Cbr>\n“Lysine may aid in reducing triglyceride levels in the blood . . . as well as it may help to synthesize carnitine which helps to prevent many health issues that involve the heart and circulatory system”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “MEN’S HEALTH MONTH” on your website:\u003C\u002Fstrong>\u003Cbr>\n“Collagen has a therapeutic role in the prevention and treatment of osteoporosis and osteoarthritis; including increased osteoblast proliferation, mineralized bone matrix formation, bone preservation and increased bone mineral density.”\u003C\u002Fp>\n\n\u003Cp>“Collagen has also been shown to stimulate bone-forming cells, protecting against excessive bone loss . . . .”\u003C\u002Fp>\n\n\u003Cp>“Useful in reducing arthritic pain.”\u003C\u002Fp>\n\n\u003Cp>“Collagen helps to keep blood vessels strong and repair those that may be weak and damaged.”\u003C\u002Fp>\n\n\u003Cp>“Amino acid help to reduce total cholesterol, low-density lipoproteins (LDL) and triglycerides.”\u003C\u002Fp>\n\n\u003Cp>“Helps to eliminate excess toxins that can damage the liver, brain, and nervous system.”\u003C\u002Fp>\n\n\u003Cp>“Assist with regeneration of the liver.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “A DIETITIAN’S PERSONAL EXPERIENCE WITH COLLAGEN” on your website:\u003C\u002Fstrong>\u003Cbr>\n“Based off of my personal experience supplementing with collagen, I found the product to be solid. . . . I was interested in taking it because I had some knee pain from overcompensating due to a tight hip joint . . . . In approximately 2 weeks of starting the product, I did notice the pain subsiding.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In the video on your YouTube channel titled “Great Lakes Gelatin: The Natural Way to Renew and Repair”:\u003C\u002Fstrong>\u003Cbr>\nIncludes image showing list of “Benefits”: “Reduce Joint Pain”\u003C\u002Fp>\n\n\u003Cp>Starting at 2:56: “Especially for people who are Celiac’s or people with autoimmune disease, it’s great in repairing that digestive tract”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On your Pinterest page, on your “Benefits of GLG” board, you pinned “10 Incredible Health Benefits of Gelatin” that links to https:\u002F\u002Fhealyeatsreal.com\u002F10-incredible-health-benefits-of-gelatin, which identifies your hydrolyzed collagen products as an option for “get[ting] more gelatin into your diet”:\u003C\u002Fstrong>\u003Cbr>\n“Gelatin is basically the cooked version of collagen . . . . gelatin is made up of some unique amino acids (such as glycine, alanine, and proline) . . . . And it’s these amino acids that provide the remarkable therapeutic benefits of gelatin . . . . Gelatin appears to benefit our joints . . . by reducing pain and inflammation that are characteristic of joint diseases such as arthritis.”\u003C\u002Fp>\n\n\u003Cp>“Gelatin also reduces inflammation in the digestive tract . . . .”\u003C\u002Fp>\n\n\u003Cp>“If this isn’t enough, there is also evidence that supports using gelatin to help: . . . Prevent auto-immune conditions”\u003C\u002Fp>\n\n\u003Cp>“Gelatin appears to be highly anti-inflammatory . . . .”\u003C\u002Fp>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Collagen Hydrolysate for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the “Why Collagen” webpage of your website www.greatlakesgelatin.com:\u003C\u002Fstrong>\u003Cbr>\n“I had very painful knees and was suffering with plantar fasciitis on one foot . . . . It has been a life changing supplement for me . . . . Karen C.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On your Facebook page, in the following posts, which link to your websitewww.greatlakesgelatin.com:\u003C\u002Fstrong>\u003Cbr>\nOctober 22, 2020 post: “5 star review from Roxie’s M. . . . I love Great Lakes collagen. It’s the only collagen that takes away my joint pains.”\u003C\u002Fp>\n\n\u003Cp>September 15, 2020 post: “5 star review from MRS. T . . . This product was recommended to me after a shoulder injury . . . . After 2 weeks using according to the directions, I was hesitant to acknowledge the improvement. I went another week and could not deny it.”\u003C\u002Fp>\n\n\u003Cp>July 27, 2020 post: “5 star review from Majnomad . . . I’ve been drinking Great Lakes Collagen Hydrolysate for several years . . . . I’ve broken just about every bone in my body. I began drinking this collagen after breaking my leg in a motorcycle accident. I truly believe it helps me heal quicker and stronger.”\u003C\u002Fp>\n\n\u003Cp>In addition, when scientific publications are used commercially by the seller of a product to market the product to consumers, such publications may become evidence of the product’s intended use. For example, under 21 CFR 101.93(g)(2)(iv)(C), a citation of a publication or reference in the labeling of a product is considered to be a claim about disease treatment or prevention if the citation refers to a disease use, and if, in the context of the labeling as a whole, the citation implies treatment or prevention of a disease. The following are examples of citations to scientific publications or references you use to market your products for disease treatment and prevention on your website www.greatlakesgelatin.com:\u003C\u002Fp>\n\n\u003Cp>Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “COLLAGEN SUPPLEMENTATION AND BONE AND JOINT HEALTH” on your website:\u003C\u002Fstrong>\u003Cbr>\n• Moskowitz, Roland. Role of collagen Hydrolysate in Bone and Joint Disease. Seminars is Arthritis and Rheumatism 2000; 30(2): 87-99.\u003Cbr>\n• Porfirio, E., Fanaro, G. Collagen supplementation as a complementary therapy for the prevention and treatment of osteoporosis and osteoarthritis: a systematic review. Rev. Bras. Geriatr. Gerontol; 2016 19(1): 153-164.\u003C\u002Fp>\n\n\u003Cp>Collagen Hydrolysate (10 oz unflavored, 16 oz unflavored, Convenience Pack (20 count unflavored), 8lb unflavored) products, which contain Type I collagen as indicated on your website\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Under the blog titled “COLLAGEN SUPPLEMENTATION AND GASTROINTESTINAL HEALTH” on your website:\u003C\u002Fstrong>\u003Cbr>\n• Ramadass, S., Jabaris, SL., Perumal RK., HairulIslam VI., Gopinath, A., Madhan, B. Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy. European Journal of Pharmaceutical Science 2016 91:216-224.\u003C\u002Fp>\n\n\u003Cp>Your Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Lauren Crivellone, Compliance Officer, Food and Drug Administration, 550 West Jackson Boulevard, Suite 1500, Chicago, IL 60661. If you have any questions with regards to this letter, please contact Lauren Crivellone at (312) 596-4157 or email lauren.crivellone@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations East-VI\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nCertified Mail\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJames Burkett\n\nRecipient Title\n\nPresident\n\nGreat Lakes Gelatin Company\n\n253 Commerce Dr., Ste 101\n\nGrayslake, IL 60030\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East-VI\n\nUnited States\n\nWARNING LETTER\n\nFY21-HAFE6-WL-03\n\nMay 10, 2021\n\nRe: 612323\n\nDear Mr. Burkett:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.greatlakesgelatin.com in March – May 2021, and has determined that you take orders there for the products Collagen Hydrolysate (10 oz unflavored and vanilla, mixed berry, lemon + lime, apple + cucumber, chocolate, and chai flavors, 16 oz unflavored, Convenience Pack (20 count unflavored), 8lb unflavored), Keto Collagen + MCT, and Collagen Endurance Plus. We have also reviewed your social media websites at www.facebook.com\u002Fgreatlakesgel\u002F and http:\u002F\u002Fwww.pinterest.com\u002Fgreatlakesgel\u002F, which direct consumers to your website www.greatlakesgelatin.com, where you take orders for your products. In addition, your website www.greatlakesgelatin.com links to your YouTube channel https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUClCQa2KGaAVEw_ROlp-dCAQ. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nCollagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products (which, as indicated on your website, contain collagen hydrolysate (also referred to as hydrolyzed collagen))\n\nOn your website www.greatlakesgelatin.com:\n\nOn the “About Great Lakes Gelatin” webpage of your website:\n\n“We pioneered the ‘original’ Collagen Hydrolysate, and this amazing product has helped thousands of people see the benefits of . . . reduced joint pain . . . .”\n\nOn the “Why Collagen” webpage of your website:\n\nArtwork with pop-up text - “Natural, Anti Inflammatory”\n\nOn the “Healthy Living” webpage of your website:\n\n“Many of our customers also report that their joint pain or discomfort has eased . . . .”\n\nOn the “FAQS” webpage of your website:\n\n“What are the benefits of collagen and gelatin? . . . Reduces joint pain”\n\nUnder the blog titled “COLLAGEN SUPPLEMENTATION AND GASTROINTESTINAL HEALTH” on your website:\n\n“Many of the amino acids in collagen protect the gastrointestinal tract by regulating stomach acid secretions, preventing stomach ulcers, helping to heal gastrointestinal lining, reducing and preventing inflammation of the GI tract . . . .”\n\n“One research study attempting to promote mucosal healing in ulcerative colitis found that by day 13 of supplementing with collagen hydrolysate rectal bleeding completely stopped.”\n\n“In the same study, there was also evidence found that collagen hydrolysate provided an anti-inflammatory effect as well as protection to the intestinal mucosa . . . .”\n\n“Many who suffer from leaky gut syndrome use collagen hydrolysate as a supplement to aid in symptom management as well.”\n\n“The amino acids glutamine, glycine lysine, serine, and threonine found in collagen hydrolysate all help . . . . Glycine . . . may protect against stomach ulcers by minimizing unnecessary stomach acid secretion.”\n\nUnder the blog titled “COLLAGEN SUPPLEMENTATION AND BONE AND JOINT HEALTH” on your website:\n\n“Collagen may help to:… reduce joint pain … and aid in repair of broken bones.”\n\n“Collagen has a therapeutic role in the prevention and treatment of osteoporosis and osteoarthritis; including increased osteoblast proliferation, mineralized bone matrix formation, bone preservation and increased bone mineral density.”\n\n“Collagen has also been shown to stimulate bone forming cells, protecting against excessive bone loss . . . .”\n\n“Several of the amino acids in collagen . . . . Glycine may help to protect against arthritis and histidine can be used to treat rheumatoid arthritis. . . . Phenylalanine helps to reduce arthritic pain.”\n\n“To summarize, supplementing with collagen may help to reduce pain from osteoarthritis, increase bone mineral density, decrease joint pain . . . .”\n\nUnder the blog titled “WHY CHOCOLATE HEARTS AREN'T THE ONLY HEART YOU SHOULD BE FOCUSED ON THIS FEBRUARY” on your website:\n\n“Lysine may aid in reducing triglyceride levels in the blood . . . as well as it may help to synthesize carnitine which helps to prevent many health issues that involve the heart and circulatory system”\n\nUnder the blog titled “MEN’S HEALTH MONTH” on your website:\n\n“Collagen has a therapeutic role in the prevention and treatment of osteoporosis and osteoarthritis; including increased osteoblast proliferation, mineralized bone matrix formation, bone preservation and increased bone mineral density.”\n\n“Collagen has also been shown to stimulate bone-forming cells, protecting against excessive bone loss . . . .”\n\n“Useful in reducing arthritic pain.”\n\n“Collagen helps to keep blood vessels strong and repair those that may be weak and damaged.”\n\n“Amino acid help to reduce total cholesterol, low-density lipoproteins (LDL) and triglycerides.”\n\n“Helps to eliminate excess toxins that can damage the liver, brain, and nervous system.”\n\n“Assist with regeneration of the liver.”\n\nUnder the blog titled “A DIETITIAN’S PERSONAL EXPERIENCE WITH COLLAGEN” on your website:\n\n“Based off of my personal experience supplementing with collagen, I found the product to be solid. . . . I was interested in taking it because I had some knee pain from overcompensating due to a tight hip joint . . . . In approximately 2 weeks of starting the product, I did notice the pain subsiding.”\n\nIn the video on your YouTube channel titled “Great Lakes Gelatin: The Natural Way to Renew and Repair”:\n\nIncludes image showing list of “Benefits”: “Reduce Joint Pain”\n\nStarting at 2:56: “Especially for people who are Celiac’s or people with autoimmune disease, it’s great in repairing that digestive tract”\n\nOn your Pinterest page, on your “Benefits of GLG” board, you pinned “10 Incredible Health Benefits of Gelatin” that links to https:\u002F\u002Fhealyeatsreal.com\u002F10-incredible-health-benefits-of-gelatin, which identifies your hydrolyzed collagen products as an option for “get[ting] more gelatin into your diet”:\n\n“Gelatin is basically the cooked version of collagen . . . . gelatin is made up of some unique amino acids (such as glycine, alanine, and proline) . . . . And it’s these amino acids that provide the remarkable therapeutic benefits of gelatin . . . . Gelatin appears to benefit our joints . . . by reducing pain and inflammation that are characteristic of joint diseases such as arthritis.”\n\n“Gelatin also reduces inflammation in the digestive tract . . . .”\n\n“If this isn’t enough, there is also evidence that supports using gelatin to help: . . . Prevent auto-immune conditions”\n\n“Gelatin appears to be highly anti-inflammatory . . . .”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Collagen Hydrolysate for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn the “Why Collagen” webpage of your website www.greatlakesgelatin.com:\n\n“I had very painful knees and was suffering with plantar fasciitis on one foot . . . . It has been a life changing supplement for me . . . . Karen C.”\n\nOn your Facebook page, in the following posts, which link to your websitewww.greatlakesgelatin.com:\n\nOctober 22, 2020 post: “5 star review from Roxie’s M. . . . I love Great Lakes collagen. It’s the only collagen that takes away my joint pains.”\n\nSeptember 15, 2020 post: “5 star review from MRS. T . . . This product was recommended to me after a shoulder injury . . . . After 2 weeks using according to the directions, I was hesitant to acknowledge the improvement. I went another week and could not deny it.”\n\nJuly 27, 2020 post: “5 star review from Majnomad . . . I’ve been drinking Great Lakes Collagen Hydrolysate for several years . . . . I’ve broken just about every bone in my body. I began drinking this collagen after breaking my leg in a motorcycle accident. I truly believe it helps me heal quicker and stronger.”\n\nIn addition, when scientific publications are used commercially by the seller of a product to market the product to consumers, such publications may become evidence of the product’s intended use. For example, under 21 CFR 101.93(g)(2)(iv)(C), a citation of a publication or reference in the labeling of a product is considered to be a claim about disease treatment or prevention if the citation refers to a disease use, and if, in the context of the labeling as a whole, the citation implies treatment or prevention of a disease. The following are examples of citations to scientific publications or references you use to market your products for disease treatment and prevention on your website www.greatlakesgelatin.com:\n\nCollagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products\n\nUnder the blog titled “COLLAGEN SUPPLEMENTATION AND BONE AND JOINT HEALTH” on your website:\n\n• Moskowitz, Roland. Role of collagen Hydrolysate in Bone and Joint Disease. Seminars is Arthritis and Rheumatism 2000; 30(2): 87-99.\n\n• Porfirio, E., Fanaro, G. Collagen supplementation as a complementary therapy for the prevention and treatment of osteoporosis and osteoarthritis: a systematic review. Rev. Bras. Geriatr. Gerontol; 2016 19(1): 153-164.\n\nCollagen Hydrolysate (10 oz unflavored, 16 oz unflavored, Convenience Pack (20 count unflavored), 8lb unflavored) products, which contain Type I collagen as indicated on your website\n\nUnder the blog titled “COLLAGEN SUPPLEMENTATION AND GASTROINTESTINAL HEALTH” on your website:\n\n• Ramadass, S., Jabaris, SL., Perumal RK., HairulIslam VI., Gopinath, A., Madhan, B. Type I collagen and its daughter peptides for targeting mucosal healing in ulcerative colitis: A new treatment strategy. European Journal of Pharmaceutical Science 2016 91:216-224.\n\nYour Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Collagen Hydrolysate, Keto Collagen + MCT, and Collagen Endurance Plus fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Lauren Crivellone, Compliance Officer, Food and Drug Administration, 550 West Jackson Boulevard, Suite 1500, Chicago, IL 60661. If you have any questions with regards to this letter, please contact Lauren Crivellone at (312) 596-4157 or email lauren.crivellone@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger\n\nProgram Division Director\n\nOffice of Human and Animal Food\n\nOperations East-VI","Great Lakes Gelatin Company","great-lakes-gelatin-company-612323-05102021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-lakes-gelatin-company-612323-05102021","2026-10-26T08:08:49.49687+00:00","2021-05-25","612323","DrugsFood & Beverages","2021-11-05","James Burkett","2026-08-20T03:07:10.29+00:00","Certified Mail","2021-05-10",{"id":183,"raw":184,"subject":78,"body_html":190,"body_text":191,"firm_name":192,"letter_id":193,"created_at":194,"fei_number":20,"letter_url":195,"updated_at":196,"action_type":23,"case_status":152,"posted_date":197,"marcs_cms_no":198,"product_type":27,"closeout_date":199,"issuing_office":200,"recipient_name":201,"body_fetched_at":202,"delivery_method":203,"recipient_title":20,"reference_number":20,"action_taken_date":204,"medical_device_id":20,"response_letter_date":20},2109,[185,186,187,188,78,13,189,13],"\u003Ctime datetime=\"2023-05-09T13:20:00Z\">05\u002F09\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-09T05:00:00Z\">12\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-nutra-pharma-inc-640210-12092022\">Premier Nutra Pharma Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-nutra-pharma-inc-640210-10112023\">\u003Ctime datetime=\"2023-10-18T04:00:00Z\">10\u002F18\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Israel Kravzov and Mr. Hector Gudino\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Premier Nutra Pharma Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5800 Newton Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carlsbad\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92008\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 9, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kravzov and Mr. Gudino:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your facility, Premier Nutra Pharma Inc., FEI 3017303868, at 5800 Newton Drive, Carlsbad, CA, from July 5 to July 8, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your correspondence dated August 17, 2022. In your correspondence, you indicated your firm never intended, represented to be, or is currently a licensed drug manufacturer. However, documents collected during the inspection indicated that you considered nasal sprays to be over-the-counter (OTC) drug products. Furthermore, you acknowledged that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> labels provided by \u003Cstrong>(b)(4)\u003C\u002Fstrong> “appeared to have medical claims.”\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufactured drug products on behalf of your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to perform an investigation into the microbial contamination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Nasal Spray batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, there was no evaluation of other drug product batches that may have been similarly contaminated, as you indicated that at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a main ingredient in several drug products you manufactured for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were visibly contaminated with insects (bees) and\u002For yeast yet were still used in production.\u003C\u002Fp>\n\n\u003Cp>The inspection also documented that \u003Cstrong>(b)(4)\u003C\u002Fstrong> Nasal Spray drug product batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>, released to the market, was also contaminated with yeast. Test results provided to you by your customer indicated at least three different samples of this lot having results for yeast greater than 20 CFU\u002Fg, with one as high as 70 CFU\u002Fg. We acknowledge that your customer voluntarily recalled the affected batch.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish written, approved procedures to prevent microbial contamination during the manufacturing operations of nasal spray OTC drug products at your facility. Specifically, your firm did not have an environmental monitoring program, did not perform any microbiological testing of facilities or equipment, and did not have established cleaning procedures or records. These conditions and practices increased the risk of contamination of the drug products your firm manufactured.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your firm failed to conduct appropriate laboratory testing of each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate batch production and control records for your manufacturing operations. Your firm indicated that you did not have production records, including batch records, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Nasal Spray batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Although you provided records consisting of emails and initial master batch records, you failed to provide and maintain manufacturing batch records for your formulation, filling, and packaging operations, including equipment used, identification of person performing each step, description of components, complete labeling controls, and actual yield. Without adequate batch records, you cannot assure the uniformity of your drug products from batch to batch.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked a quality unit (QU) and failed to establish written procedures defining QU responsibilities and controls. For example, your firm failed to establish adequate procedures for reviewing and approving batch records prior to drug product release, annual product reviews, deviations, corrective action and preventive action (CAPA), complaints, maintaining retain samples, and conducting recalls.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility as a drug manufacturer to comply with all CGMP requirements including, but not limited to, ensuring that the roles and responsibilities of QU are understood and fulfilled.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A thorough and independent evaluation of your operations to determine if any additional products you released and that remain within expiry, are drugs as defined by the FD&amp;C Act. Include a list of all products released, including examples of labelling.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For all drug products that have been manufactured in your facility, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\n\t\u003Cli>All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fli>\n\t\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients, and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices ensuring you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A risk assessment of products released to the U.S. market without adequate and approved production and control documentation.\u003C\u002Fli>\n\t\u003Cli>An independent, comprehensive assessment and remediation plan to ensure your QU is established with the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your and your contract manufacturers’ operations to evaluate adherence to appropriate practices in functions that could affect drug quality.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See the FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting drug CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier CMS 640210. Electronic responses may be submitted to ORAPHARM4_Responses@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or send your written responses to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n1907 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact LCDR Rumany Penn, compliance officer, at (949) 608-4409, or by email at Rumany.Penn@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003C\u002Fp>\n\n\u003Cp>Director, Division of Pharmaceutical Quality Operations IV SP:rp\u003C\u002Fp>\n\n\u003Cp>cc: Mr. Hector Gudino, Co-CEO\u003Cbr>\nPremier Nutra Pharma Inc.\u003Cbr>\n5800 Newton Drive\u003Cbr>\nCarlsbad, CA 92008\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Israel Kravzov and Mr. Hector Gudino\n\nRecipient Title\n\nCo-CEO\n\nPremier Nutra Pharma Inc.\n\n5800 Newton Drive\n\nCarlsbad, CA 92008\n\nUnited States\n\n(b)(6)\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nDecember 9, 2022\n\nDear Mr. Kravzov and Mr. Gudino:\n\nThe U.S. Food and Drug Administration inspected your facility, Premier Nutra Pharma Inc., FEI 3017303868, at 5800 Newton Drive, Carlsbad, CA, from July 5 to July 8, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your correspondence dated August 17, 2022. In your correspondence, you indicated your firm never intended, represented to be, or is currently a licensed drug manufacturer. However, documents collected during the inspection indicated that you considered nasal sprays to be over-the-counter (OTC) drug products. Furthermore, you acknowledged that the (b)(4) labels provided by (b)(4) “appeared to have medical claims.”\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou manufactured drug products on behalf of your customer, (b)(4). Your firm failed to perform an investigation into the microbial contamination of (b)(4) Nasal Spray batch (b)(4). Furthermore, there was no evaluation of other drug product batches that may have been similarly contaminated, as you indicated that at least (b)(4), a main ingredient in several drug products you manufactured for (b)(4), were visibly contaminated with insects (bees) and\u002For yeast yet were still used in production.\n\nThe inspection also documented that (b)(4) Nasal Spray drug product batch (b)(4), released to the market, was also contaminated with yeast. Test results provided to you by your customer indicated at least three different samples of this lot having results for yeast greater than 20 CFU\u002Fg, with one as high as 70 CFU\u002Fg. We acknowledge that your customer voluntarily recalled the affected batch.\n\n2. Your firm failed to establish and follow appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile (21 CFR 211.113(a)).\n\nYour firm failed to establish written, approved procedures to prevent microbial contamination during the manufacturing operations of nasal spray OTC drug products at your facility. Specifically, your firm did not have an environmental monitoring program, did not perform any microbiological testing of facilities or equipment, and did not have established cleaning procedures or records. These conditions and practices increased the risk of contamination of the drug products your firm manufactured.\n\nFurthermore, your firm failed to conduct appropriate laboratory testing of each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\n3. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\n\nYour firm lacked adequate batch production and control records for your manufacturing operations. Your firm indicated that you did not have production records, including batch records, for (b)(4) Nasal Spray batch (b)(4). Although you provided records consisting of emails and initial master batch records, you failed to provide and maintain manufacturing batch records for your formulation, filling, and packaging operations, including equipment used, identification of person performing each step, description of components, complete labeling controls, and actual yield. Without adequate batch records, you cannot assure the uniformity of your drug products from batch to batch.\n\n4. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and 211.22(d)).\n\nYour firm lacked a quality unit (QU) and failed to establish written procedures defining QU responsibilities and controls. For example, your firm failed to establish adequate procedures for reviewing and approving batch records prior to drug product release, annual product reviews, deviations, corrective action and preventive action (CAPA), complaints, maintaining retain samples, and conducting recalls.\n\nIt is your responsibility as a drug manufacturer to comply with all CGMP requirements including, but not limited to, ensuring that the roles and responsibilities of QU are understood and fulfilled.\n\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nIn response to this letter, provide:\n\nA thorough and independent evaluation of your operations to determine if any additional products you released and that remain within expiry, are drugs as defined by the FD&C Act. Include a list of all products released, including examples of labelling.\n\nFor all drug products that have been manufactured in your facility, provide the following:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nComplete investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\n\nAll chemical and microbial test methods used to analyze each of your drug products.\n\nA summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients, and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices ensuring you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\nA risk assessment of products released to the U.S. market without adequate and approved production and control documentation.\n\nAn independent, comprehensive assessment and remediation plan to ensure your QU is established with the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your and your contract manufacturers’ operations to evaluate adherence to appropriate practices in functions that could affect drug quality.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See the FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations if your firm intends to resume manufacturing drugs for the U.S. market, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting drug CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility. If you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with unique identifier CMS 640210. Electronic responses may be submitted to ORAPHARM4_Responses@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or send your written responses to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n1907 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have questions regarding this letter, please contact LCDR Rumany Penn, compliance officer, at (949) 608-4409, or by email at Rumany.Penn@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV SP:rp\n\ncc: Mr. Hector Gudino, Co-CEO\n\nPremier Nutra Pharma Inc.\n\n5800 Newton Drive\n\nCarlsbad, CA 92008\n\n(b)(6)","Premier Nutra Pharma Inc.","premier-nutra-pharma-inc-640210-12092022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-nutra-pharma-inc-640210-12092022","2026-10-26T08:09:43.501551+00:00","2023-05-09","640210","2023-10-18","Division of Pharmaceutical Quality Operations IV","Mr. Israel Kravzov and Mr. Hector Gudino","2026-08-20T01:07:37.415+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-12-09",{"id":206,"raw":207,"subject":98,"body_html":211,"body_text":212,"firm_name":213,"letter_id":214,"created_at":103,"fei_number":20,"letter_url":215,"updated_at":216,"action_type":23,"case_status":24,"posted_date":217,"marcs_cms_no":20,"product_type":108,"closeout_date":20,"issuing_office":97,"recipient_name":218,"body_fetched_at":219,"delivery_method":220,"recipient_title":20,"reference_number":20,"action_taken_date":221,"medical_device_id":20,"response_letter_date":20},74,[208,209,210,97,98,13,13,13],"\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-17T04:00:00Z\">04\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-enterprise-727852-group\">Great Enterprise - Group - Inc. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Phat V. Phung\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Great Enterprise - Group - Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2660 Waiwai Loop\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honolulu\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96819-1992\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 17, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 727852\u003C\u002Fp>\u003Cp>Dear Mr. Phung:\u003C\u002Fp>\u003Cp>On April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great Enterprise (Group) Inc., located at 2660 Waiwai Loop, Honolulu, HI 96819-1992. We also conducted inspections on April 11 and 24, 2019; January 28 through February 10, 2021; and July 24, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response dated April 15, 2026, in which you stated that you have initiated steps to develop an FSVP program by requesting hazard analysis documents from your suppliers and exploring training options. You also committed to establishing a comprehensive FSVP program and achieving full compliance by your next inspection. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Hoisin Sauce imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Canned Bamboo Shoots Slices imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Rice Stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection you provided the investigator with the following documents: copies of product labels, invoices, Entry Summaries, Certificates of Analysis, a Certificate of Ingredients, a flow chart, a HACCP plan, and third-party food safety certifications including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You told our investigator that you requested these documents from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\u003Cp>For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to Canned Bamboo Shoots Slices imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 727852 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPhat V. Phung\n\nRecipient Title\n\nPresident\n\nGreat Enterprise - Group - Inc.\n\n2660 Waiwai Loop\n\nHonolulu, HI 96819-1992\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nApril 17, 2026\nWARNING LETTER\nRe: CMS # 727852\nDear Mr. Phung:\nOn April 2, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Great Enterprise (Group) Inc., located at 2660 Waiwai Loop, Honolulu, HI 96819-1992. We also conducted inspections on April 11 and 24, 2019; January 28 through February 10, 2021; and July 24, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable United States food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response dated April 15, 2026, in which you stated that you have initiated steps to develop an FSVP program by requesting hazard analysis documents from your suppliers and exploring training options. You also committed to establishing a comprehensive FSVP program and achieving full compliance by your next inspection. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\n(b)(4) Hoisin Sauce imported from (b)(4), located in (b)(4).\nCanned Bamboo Shoots Slices imported from (b)(4), located in (b)(4).\n(b)(4) Rice Stick imported from (b)(4), located in (b)(4).\nRice Stick imported from (b)(4), located in (b)(4).\n(b)(4) Rice Stick imported from (b)(4), located in (b)(4).\nDuring our inspection you provided the investigator with the following documents: copies of product labels, invoices, Entry Summaries, Certificates of Analysis, a Certificate of Ingredients, a flow chart, a HACCP plan, and third-party food safety certifications including (b)(4). You told our investigator that you requested these documents from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\nFor thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to Canned Bamboo Shoots Slices imported from (b)(4), located in (b)(4) were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Celena Ngo, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Celena Ngo via email at celena.ngo@fda.hhs.gov. Please reference CMS # 727852 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Great Enterprise - Group - Inc.","great-enterprise-727852-group","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-enterprise-727852-group","2026-10-26T08:08:49.369676+00:00","2026-06-23","Phat V. Phung","2026-08-19T04:33:08.215+00:00","Via Express Delivery","2026-04-17",{"id":223,"raw":224,"subject":78,"body_html":229,"body_text":230,"firm_name":231,"letter_id":232,"created_at":45,"fei_number":20,"letter_url":233,"updated_at":234,"action_type":23,"case_status":24,"posted_date":235,"marcs_cms_no":236,"product_type":27,"closeout_date":20,"issuing_office":237,"recipient_name":238,"body_fetched_at":239,"delivery_method":240,"recipient_title":20,"reference_number":20,"action_taken_date":241,"medical_device_id":20,"response_letter_date":20},1725,[225,226,227,228,78,13,13,13],"\u003Ctime datetime=\"2023-11-21T14:20:00Z\">11\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-26T04:00:00Z\">10\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrenntag-great-lakes-llc-660268-10262023\">Brenntag Great Lakes, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel Arneson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Brenntag Great Lakes, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4420 North Harley Davidson Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wauwatosa\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53225-4311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>10\u002F26\u002F2023\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003Cbr>\nCASE# 660268\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Arneson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brenntag Great Lakes, LLC, FEI: 2126821, at N59W14765 Bobolink Avenue, Menomonee Falls, WI 53051-5901, from April 26 to May 5, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response and subsequent correspondence to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 70% Hand Sanitizer Solution, as well as non-drug products including Class 2 solvents and industrial chemicals, including automotive brake parts cleaner using the same equipment. This was noted during a previous inspection and as a corrective action you stated you would discontinue the use of non-dedicated blending tank equipment in the manufacture of OTC drug products. However, our investigator observed that you continued to use non-dedicated blending tank equipment to manufacture OTC drug products. In your response, you explained that while there was a decision to discontinue using non-dedicated tanks, the decision was not effectively communicated to the production team.\u003C\u002Fp>\n\n\u003Cp>It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\u003C\u002Fli>\n\t\u003Cli>If you intend to continue manufacturing both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A review of your production records (e.g. tank logbooks) to determine if other drug products within expiry were made on non-dedicated equipment, and if so, provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate procedures to ensure the QU has the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate written procedures for production and process controls (e.g., mixer speed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Sanitizer Solution) (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Appropriate control over computer systems (21 CFR 211.68(b)).\u003C\u002Fli>\n\t\u003Cli>Performance of periodic product reviews (21 CFR 211.180(e)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such as your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>Timelines for completed process performance qualification for marketed drug products for which a state of control has not been adequately\u002Ffully established.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In previous inspections ending on September 10, 2014 and August 2, 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to Case # 660268. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian Nicholson, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nDirector of Compliance\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>For\u003C\u002Fp>\n\n\u003Cp>Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nKaoni N. Rhodes\u003Cbr>\nRegional Health, Safety, Quality and Environmental Manager\u003Cbr>\nBrenntag Great Lakes, LLC\u003Cbr>\n4420 N. Harley Davidson Avenue\u003Cbr>\nWauwatosa, WI 53225\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel Arneson\n\nRecipient Title\n\nPresident\n\nBrenntag Great Lakes, LLC\n\n4420 North Harley Davidson Avenue\n\nWauwatosa, WI 53225-4311\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\n10\u002F26\u002F2023\n\nWARNING LETTER\n\nCASE# 660268\n\nDear Mr. Arneson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Brenntag Great Lakes, LLC, FEI: 2126821, at N59W14765 Bobolink Avenue, Menomonee Falls, WI 53051-5901, from April 26 to May 5, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe acknowledge receipt of your response and subsequent correspondence to our Form FDA 483. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactures over-the-counter (OTC) hand sanitizer drug product, (b)(4) 70% Hand Sanitizer Solution, as well as non-drug products including Class 2 solvents and industrial chemicals, including automotive brake parts cleaner using the same equipment. This was noted during a previous inspection and as a corrective action you stated you would discontinue the use of non-dedicated blending tank equipment in the manufacture of OTC drug products. However, our investigator observed that you continued to use non-dedicated blending tank equipment to manufacture OTC drug products. In your response, you explained that while there was a decision to discontinue using non-dedicated tanks, the decision was not effectively communicated to the production team.\n\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Inadequate removal of active ingredients and product residues from surfaces of non-dedicated manufacturing equipment can lead to contamination of drug products subsequently manufactured on that equipment.\n\nIn response to this letter, provide:\n\nConfirmation of whether you will discontinue manufacturing drugs on shared equipment in your facility and implement appropriate controls to prevent cross-contamination.\n\nIf you intend to continue manufacturing both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will maintain appropriate separation with dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA review of your production records (e.g. tank logbooks) to determine if other drug products within expiry were made on non-dedicated equipment, and if so, provide a risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\nAdequate procedures to ensure the QU has the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\n\nAdequate written procedures for production and process controls (e.g., mixer speed for (b)(4) Hand Sanitizer Solution) (21 CFR 211.100(a)).\n\nAppropriate control over computer systems (21 CFR 211.68(b)).\n\nPerformance of periodic product reviews (21 CFR 211.180(e)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such as your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nTimelines for completed process performance qualification for marketed drug products for which a state of control has not been adequately\u002Ffully established.\n\nRepeat Observations at Facility\n\nIn previous inspections ending on September 10, 2014 and August 2, 2019, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to Case # 660268. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian Nicholson, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Brian Nicholson at (630) 207-9337.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nDirector of Compliance\n\nDivision of Pharmaceutical Quality Operations III\n\nFor\n\nJeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\nCc:\n\nKaoni N. Rhodes\n\nRegional Health, Safety, Quality and Environmental Manager\n\nBrenntag Great Lakes, LLC\n\n4420 N. Harley Davidson Avenue\n\nWauwatosa, WI 53225\n\n____________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Brenntag Great Lakes, LLC","brenntag-great-lakes-llc-660268-10262023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrenntag-great-lakes-llc-660268-10262023","2026-10-26T08:08:08.858268+00:00","2023-11-21","660268","Division of Pharmaceutical Quality Operations III","Mr. Daniel Arneson","2026-08-20T00:29:21.919+00:00","UPS Next Day","2023-10-26",{"id":243,"raw":244,"subject":98,"body_html":249,"body_text":250,"firm_name":251,"letter_id":252,"created_at":125,"fei_number":20,"letter_url":253,"updated_at":254,"action_type":23,"case_status":24,"posted_date":255,"marcs_cms_no":256,"product_type":108,"closeout_date":20,"issuing_office":248,"recipient_name":257,"body_fetched_at":258,"delivery_method":220,"recipient_title":20,"reference_number":20,"action_taken_date":259,"medical_device_id":20,"response_letter_date":20},1088,[245,246,247,248,98,13,13,13],"\u003Ctime datetime=\"2025-01-21T14:20:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-18T05:00:00Z\">12\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-fresh-growers-llc-698646-12182024\">Premium Fresh Growers LLC\u003C\u002Fa>","Division of Southwest Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Carlos Alberto Toto Cortes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Premium Fresh Growers LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4900 W. Expressway 83, Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McAllen\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78501\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dc@premiumfreshgrowers.com\"> dc@premiumfreshgrowers.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 18, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS 698646\u003C\u002Fp>\u003Cp>Dear Mr. Cortes:\u003C\u002Fp>\u003Cp>On 10\u002F24\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Premium Fresh Growers LLC located at 4900 W. Expressway 83, Suite 202 McAllen, Texas, 78501. We also conducted an inspection on 05\u002F25\u002F2023-07\u002F27\u002F2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import:\u003C\u002Fp>\u003Cul>\u003Cli>Limes from the foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Cilantro from the foreign supplier, Carlos Alberto Toto Cortes; Mexico\u003C\u002Fli>\u003Cli>Carrots from the foreign supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Limes imported from, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Cilantro imported from, Carlos Alberto Toto Cortes, located in Mexico\u003C\u002Fli>\u003Cli>Carrots imported from, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Zumera Ajani, Compliance Officer, Division of Southwest Imports, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Zumera Ajani via email at Zumera.Ajani@fda.hhs.gov. Please reference CMS # 698646 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Stacy Below&nbsp;&nbsp;\u003Cbr>Acting Program&nbsp;&nbsp;\u003Cbr>Director Division of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Carlos Alberto Toto Cortes\n\nRecipient Title\n\nPresident\u002FOwner\n\nPremium Fresh Growers LLC\n\n4900 W. Expressway 83, Suite 202\n\nMcAllen, TX 78501\n\nUnited States\n\ndc@premiumfreshgrowers.com\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nDecember 18, 2024\nWARNING LETTER\nRe: CMS 698646\nDear Mr. Cortes:\nOn 10\u002F24\u002F2024-11\u002F25\u002F2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Premium Fresh Growers LLC located at 4900 W. Expressway 83, Suite 202 McAllen, Texas, 78501. We also conducted an inspection on 05\u002F25\u002F2023-07\u002F27\u002F2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import:\nLimes from the foreign supplier, (b)(4)\nCilantro from the foreign supplier, Carlos Alberto Toto Cortes; Mexico\nCarrots from the foreign supplier, (b)(4)\nBecause of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on 11\u002F25\u002F2024.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nLimes imported from, (b)(4)\nCilantro imported from, Carlos Alberto Toto Cortes, located in Mexico\nCarrots imported from, (b)(4)\nYou import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Zumera Ajani, Compliance Officer, Division of Southwest Imports, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Zumera Ajani via email at Zumera.Ajani@fda.hhs.gov. Please reference CMS # 698646 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nStacy Below\nActing Program\nDirector Division of Southwest Imports","Premium Fresh Growers LLC","premium-fresh-growers-llc-698646-12182024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-fresh-growers-llc-698646-12182024","2026-10-26T08:09:43.619686+00:00","2025-01-21","698646","Mr. Carlos Alberto Toto Cortes","2026-08-19T17:04:07.792+00:00","2024-12-18",{"id":261,"raw":262,"subject":98,"body_html":268,"body_text":269,"firm_name":270,"letter_id":271,"created_at":45,"fei_number":20,"letter_url":272,"updated_at":273,"action_type":23,"case_status":152,"posted_date":274,"marcs_cms_no":275,"product_type":108,"closeout_date":276,"issuing_office":277,"recipient_name":278,"body_fetched_at":279,"delivery_method":220,"recipient_title":20,"reference_number":20,"action_taken_date":280,"medical_device_id":20,"response_letter_date":20},1969,[263,264,265,266,98,13,267,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-14T04:00:00Z\">07\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-food-supplies-llc-656160-07142023\">Premier Food Supplies LLC\u003C\u002Fa>"," Division of Northern Border Imports ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-food-supplies-llc-656160-07312024\">\u003Ctime datetime=\"2024-08-13T04:00:00Z\">08\u002F13\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jagdish Rughani\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Premier Food Supplies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1783 Thunderbird\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Troy\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48084-5465\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Northern Border Imports \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>07\u002F14\u002F2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS #656160\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jagdish Rughani:\u003C\u002Fp>\n\n\u003Cp>On March 14 through March 23, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Premier Food Supplies LLC, located at 1783 Thunderbird Troy, MI 48084-5465. We also conducted inspections on July 16, 2020 and September 12, 2017. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import from the foreign suppliers indicated in the attached list and for the Boondi Plain (Boondi Salted) and the Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, and the Cut Mango Pickle with Garlic imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your written response dated April 10, 2023, and we address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods from the foreign suppliers indicated in the attached list.\u003C\u002Fp>\n\n\u003Cp>On April 10, 2023, you emailed our investigator a variety of documents, including your FSVP compliance manual, an SOP on reviewing a hazard analysis, an SOP on reviewing compliance status, and an SOP on determining appropriate verification activities. These documents appear to be general SOPs on how to establish FSVPs for the foods you import, but your response did not include any documents regarding the specific foods and foreign suppliers indicated in the attached list. Thus, the documents you provided, on their own, do not constitute an FSVP for the identified foods and foreign suppliers, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\n\n\u003Cp>2. You did not meet the requirement to conduct a written hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). Specifically, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, while you obtained the hazard analysis for each of these products from your foreign supplier, you did not document your review and assessment of the hazard analyses or that the hazard analyses were conducted by a qualified individual, as required under 21 CFR 1.504(d).\u003C\u002Fp>\n\n\u003Cp>In your written response dated April 10, 2023, you provided a document titled, “SOP Reviewing Hazard Analysis”; however, your response did not include documentation of your review and assessment of the hazard analyses you obtained from your foreign supplier for your Boondi Plain (Boondi Salted) and Nimbu Masala. Likewise, although your response included a letter to your foreign supplier asking them to share the list of their qualified individuals and what makes them qualified, to date, you have not provided documentation that the hazard analyses were conducted by a qualified individual.\u003C\u002Fp>\n\n\u003Cp>3. You did not meet the requirement to evaluate your foreign supplier’s performance and the risk posed by the food, as required by 21 CFR 1.505(a), and document your approval of your foreign suppliers based on this evaluation, as required by 21 CFR 1.505(b). Specifically, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, and Cut Mango Pickle with Garlic imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not provide documentation that you have evaluated your foreign supplier’s performance and the risk posed by the food, as required by 21 CFR 1.505(a), or your approval of these suppliers, as required by 21 CFR 1.505(b).\u003C\u002Fp>\n\n\u003Cp>In your written response dated April 10, 2023, you provided a document titled, “SOP Review compliance status”; however, your response did not include documentation that you have evaluated your foreign supplier’s performance and the risk posed by the food for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd. or your Cut Mango Pickle with Garlic imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. You did not meet the requirement to perform foreign supplier verification activities as required by 21 CFR 1.506. Specifically, you did not document your determination of the appropriate supplier verification activity or activities, including the frequency with which the activity or activities must be conducted, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd. and Cut Mango Pickle with Garlic imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 1.506(d), nor did you conduct (and document) or obtain documentation of one or more appropriate supplier verification activities for each of these foreign suppliers before importing these foods and periodically thereafter, as required by 21 CFR 1.506(e).\u003C\u002Fp>\n\n\u003Cp>In your response dated April 10, 2023, you provided a document titled, “SOP Determine the appropriate Verification Activities”; however, your response did not include information related to your determination of appropriate verification activities for these foreign suppliers or documentation of any verification activities that you conducted or reviewed for these foreign suppliers.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation).\u003C\u002Fp>\n\n\u003Cp>If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports, at Alyssa.Wenke@fda.hhs.gov. If you have any questions regarding this letter, you may contact CO Wenke via email. Please reference CMS #656160 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Keith J. Jasukaitis\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northern Border Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJagdish Rughani\n\nPremier Food Supplies LLC\n\n1783 Thunderbird\n\nTroy, MI 48084-5465\n\nUnited States\n\nIssuing Office:\n\nDivision of Northern Border Imports\n\nUnited States\n\n07\u002F14\u002F2023\n\nWARNING LETTER\n\nRe: CMS #656160\n\nDear Mr. Jagdish Rughani:\n\nOn March 14 through March 23, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Premier Food Supplies LLC, located at 1783 Thunderbird Troy, MI 48084-5465. We also conducted inspections on July 16, 2020 and September 12, 2017. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import from the foreign suppliers indicated in the attached list and for the Boondi Plain (Boondi Salted) and the Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, and the Cut Mango Pickle with Garlic imported from (b)(4), located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your written response dated April 10, 2023, and we address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods from the foreign suppliers indicated in the attached list.\n\nOn April 10, 2023, you emailed our investigator a variety of documents, including your FSVP compliance manual, an SOP on reviewing a hazard analysis, an SOP on reviewing compliance status, and an SOP on determining appropriate verification activities. These documents appear to be general SOPs on how to establish FSVPs for the foods you import, but your response did not include any documents regarding the specific foods and foreign suppliers indicated in the attached list. Thus, the documents you provided, on their own, do not constitute an FSVP for the identified foods and foreign suppliers, as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\n\n2. You did not meet the requirement to conduct a written hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. Although you may meet this requirement by reviewing and assessing the hazard analysis conducted by another entity using a qualified individual, you must document your review and assessment of that hazard analysis, including documenting that the hazard analysis was conducted by a qualified individual (21 CFR 1.504(d)). Specifically, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, while you obtained the hazard analysis for each of these products from your foreign supplier, you did not document your review and assessment of the hazard analyses or that the hazard analyses were conducted by a qualified individual, as required under 21 CFR 1.504(d).\n\nIn your written response dated April 10, 2023, you provided a document titled, “SOP Reviewing Hazard Analysis”; however, your response did not include documentation of your review and assessment of the hazard analyses you obtained from your foreign supplier for your Boondi Plain (Boondi Salted) and Nimbu Masala. Likewise, although your response included a letter to your foreign supplier asking them to share the list of their qualified individuals and what makes them qualified, to date, you have not provided documentation that the hazard analyses were conducted by a qualified individual.\n\n3. You did not meet the requirement to evaluate your foreign supplier’s performance and the risk posed by the food, as required by 21 CFR 1.505(a), and document your approval of your foreign suppliers based on this evaluation, as required by 21 CFR 1.505(b). Specifically, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd., located in India, and Cut Mango Pickle with Garlic imported from (b)(4), located in (b)(4), you did not provide documentation that you have evaluated your foreign supplier’s performance and the risk posed by the food, as required by 21 CFR 1.505(a), or your approval of these suppliers, as required by 21 CFR 1.505(b).\n\nIn your written response dated April 10, 2023, you provided a document titled, “SOP Review compliance status”; however, your response did not include documentation that you have evaluated your foreign supplier’s performance and the risk posed by the food for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd. or your Cut Mango Pickle with Garlic imported from (b)(4).\n\n4. You did not meet the requirement to perform foreign supplier verification activities as required by 21 CFR 1.506. Specifically, you did not document your determination of the appropriate supplier verification activity or activities, including the frequency with which the activity or activities must be conducted, for your Boondi Plain (Boondi Salted) and Nimbu Masala imported from Haldiram Snacks Pvt. Ltd. and Cut Mango Pickle with Garlic imported from (b)(4), as required by 21 CFR 1.506(d), nor did you conduct (and document) or obtain documentation of one or more appropriate supplier verification activities for each of these foreign suppliers before importing these foods and periodically thereafter, as required by 21 CFR 1.506(e).\n\nIn your response dated April 10, 2023, you provided a document titled, “SOP Determine the appropriate Verification Activities”; however, your response did not include information related to your determination of appropriate verification activities for these foreign suppliers or documentation of any verification activities that you conducted or reviewed for these foreign suppliers.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation).\n\nIf you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Alyssa Wenke, Compliance Officer, Division of Northern Border Imports, at Alyssa.Wenke@fda.hhs.gov. If you have any questions regarding this letter, you may contact CO Wenke via email. Please reference CMS #656160 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nKeith J. Jasukaitis\n\nProgram Division Director\n\nDivision of Northern Border Imports","Premier Food Supplies LLC","premier-food-supplies-llc-656160-07142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-food-supplies-llc-656160-07142023","2026-10-26T08:09:43.429124+00:00","2023-08-01","656160","2024-08-13","Division of Northern Border Imports","Jagdish Rughani","2026-08-20T00:50:35.748+00:00","2023-07-14",{"id":282,"raw":283,"subject":288,"body_html":289,"body_text":290,"firm_name":291,"letter_id":292,"created_at":83,"fei_number":20,"letter_url":293,"updated_at":294,"action_type":23,"case_status":24,"posted_date":295,"marcs_cms_no":296,"product_type":27,"closeout_date":20,"issuing_office":287,"recipient_name":20,"body_fetched_at":297,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":298,"medical_device_id":20,"response_letter_date":20},2751,[284,285,286,287,288,13,13,13],"\u003Ctime datetime=\"2022-04-12T13:20:00Z\">04\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-30T04:00:00Z\">03\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremiumlightsuppliercom-622056-03302022\">premiumlightsupplier.com\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unlawful Sale of Schedule II Stimulants to Consumers over the Internet","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>premiumlightsupplier.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>TO: www.premiumlightsupplier.com\u003C\u002Fp>\n\n\u003Cp>FROM: The United States Food and Drug Administration and The United States Drug Enforcement Administration\u003C\u002Fp>\n\n\u003Cp>RE: Notice of Unlawful Sale of Schedule II Stimulants to United States Consumers Over the Internet\u003C\u002Fp>\n\n\u003Cp>DATE: March 30, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This is to advise you that based on the United States (U.S.) Drug Enforcement Administration’s (DEA) review, www.premiumlightsupplier.com unlawfully offers to distribute or dispense stimulants that are Schedule II controlled substances, including amphetamine drug products, and advertises their sale in violation of the Ryan Haight Online Pharmacy Consumer Protection Act (RHA), P.L. 110-425 (October 15, 2008), as codified at 21 U.S.C. § 841(h) and § 843(c). In addition, based on the U.S. Food and Drug Administration’s (FDA) review, the FDA has observed that www.premiumlightsupplier.com introduces into interstate commerce amphetamine drug products that are misbranded in violation of sections 301(a), 301(k), and 503(b) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(k), and 353(b)].\u003C\u002Fp>\n\n\u003Cp>Schedule II stimulants have an acknowledged high potential for abuse, and it is important to address the public health impact of their diversion and nonmedical use. Diversion is the primary source of prescription stimulants for nonmedical use, and nonmedical use is most frequent among young adults and college students. Polysubstance use is common among those who use prescription stimulants nonmedically, with individuals frequently co-using illicit drugs and\u002For prescription opioids. These concerns come against a backdrop of rising mortality from psychostimulant-involved overdoses, which involve illicit stimulants the vast majority of the time, but sometimes involve prescription stimulants.\u003C\u002Fp>\n\n\u003Cp>The easy availability of these stimulants via the Internet poses additional significant risks to U.S. consumers. Additionally, the sale of misbranded drugs, including misbranded stimulants, poses an inherent risk to consumers who purchase those products. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\u003C\u002Fp>\n\n\u003Cp>As set forth more fully in this Warning Letter, we request that you take any necessary corrective action and notify DEA and FDA of any remedial steps that you have taken to address any violations of Federal law. This letter also provides a procedure if you wish to contest this Warning Letter with respect to your website(s). After 15 days, failure to adequately address this matter may result in further action by DEA and FDA including potentially contacting the domain name registrar(s) associated with your website(s) and informing them of your actions.\u003C\u002Fp>\n\n\u003Cp>Under the RHA, an “online pharmacy” is a “person, entity, or Internet site, whether in the U.S. or abroad, that knowingly or intentionally delivers, distributes, or dispenses, or offers or attempts to deliver, distribute, or dispense, a controlled substance by means of the Internet.” 21 U.S.C. § 802(52)(A) (emphasis added). It is unlawful to knowingly or intentionally “deliver, distribute, or dispense a controlled substance by means of the Internet, except as authorized [by the Controlled Substances Act (CSA)],” or to knowingly or intentionally aid or abet such activity. 21 U.S.C. § 841(h)(1). This includes, for example, knowingly or intentionally “delivering, distributing, or dispensing a controlled substance by means of the Internet by an online pharmacy that is not validly registered” with a modified DEA registration authorizing such activity, see 21 U.S.C. § 841(h)(2)(A), or knowingly or intentionally serving as an “agent, intermediary, or other entity that causes the Internet to be used to bring together a buyer and seller to engage in the dispensing of a controlled substance” without a modified DEA registration. 21 U.S.C. § 841(h)(2)(C).\u003C\u002Fp>\n\n\u003Cp>In addition, under the RHA, it is also unlawful “for any person to knowingly or intentionally use the Internet, or cause the Internet to be used, to advertise the sale of, or to offer to sell, distribute, or dispense, a controlled substance where such sale, distribution or dispensing is not authorized by [the CSA] or by the Controlled Substances Import and Export Act” (CSIEA). 21 U.S.C. § 843(c)(2)(A). Examples include “knowingly or intentionally causing the placement on the Internet of an advertisement that refers to or directs prospective buyers to Internet sellers of controlled substances” who do not possess a valid modified DEA registration. 21 U.S.C. § 843(c)(2)(B) (with limitations described in 21 U.S.C. § 843(c)(2)(C)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>No Modified DEA Registration Exists for Your Website(s)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your website(s) constitutes an “online pharmacy” because it is an Internet site that knowingly or intentionally offers to deliver, distribute, or dispense a controlled substance by means of the Internet. 21 U.S.C. § 802(52). Moreover, as the owner and domain name subscriber responsible for operation of the website(s), you are serving as an agent or other entity that causes the Internet to be used to bring together buyers and sellers for the purpose of dispensing a controlled substance. DEA has determined that you are not in possession of a modified DEA registration authorizing you to engage in such activity. Accordingly, your actions constitute a violation of U.S. law, which are subject to criminal penalties and civil enforcement.\u003C\u002Fp>\n\n\u003Cp>In addition, you knowingly or intentionally use the Internet to advertise the sale of controlled substances by directing prospective buyers to Internet sellers of controlled substances who do not possess a valid modified DEA registration. You do not possess a valid modified DEA registration authorizing such activity, and your actions do not fall into the exceptions of 21 U.S.C. § 843(c)(2)(C). Therefore, your website(s) is operating in violation of U.S. law, which may be enforced through criminal penalties and civil enforcement.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug(s)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Certain products offered for sale by www.premiumlightsupplier.com are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>For example, www.premiumlightsupplier.com offers an amphetamine drug product for sale listed as “Adderall 20mg | 30mg.” Adderall is the brand name of an FDA-approved drug for the treatment of attention deficit hyperactive disorder (ADHD) and narcolepsy that is only available by prescription. Using the brand name of the drug product Adderall indicates that this product is intended to treat ADHD and narcolepsy. FDA-approved Adderall bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning indicates that amphetamines, including Adderall, have a high potential for abuse and dependence.\u003C\u002Fp>\n\n\u003Cp>The FDA-approved product Adderall is a stimulant medication. All stimulants that have been approved for marketing by FDA are limited by an approved new drug application to use under the supervision of a licensed practitioner to administer such drugs. Therefore, Adderall is a prescription drug as defined in section 503(b)(1)(A) of the FD&amp;C Act (21 U.S.C. § 353(b)(1)(A)), because, in light of its toxicity or potential for harmful effects, the method of its use, or the collateral measures necessary for its use, it is not safe for use except under the supervision of a practitioner licensed by law to administer such a drug. By offering the aforementioned drug without requiring a prescription, www.premiumlightsupplier.com jeopardizes patient safety and misbrands the drug under section 503(b)(1) of the FD&amp;C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)]. By offering this drug for sale to U.S. consumers, www.premiumlightsupplier.com is also causing the introduction of a misbranded drug into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. It is your responsibility to ensure that all products you offer for sale on your website(s) are in compliance with Federal law, including but not limited to the RHA and its implementing regulations, as well as the FD&amp;C Act and its implementing regulations. You should take prompt action to address any violations of the RHA and the FD&amp;C Act. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. Nothing in this letter should be deemed to preclude any other action, criminal or civil, by U.S. authorities.\u003C\u002Fp>\n\n\u003Cp>Please notify DEA and FDA, in writing, within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the RHA and FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003Cbr>\n\u003Cbr>\nAfter 15 days, DEA and FDA may take any additional actions that they determine to be necessary, potentially including contacting the domain name registrar(s) associated with your website(s) and informing them of your actions. Please note that the transmission of this Warning Letter does not prohibit DEA or FDA from taking any or all other actions permitted by law, including the initiation of civil or criminal proceedings against you, your website(s), or materials that you have intended for distribution.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded drugs may be detained or refused admission. FDA may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\n\n\u003Cp>Your response to DEA should be sent to the following e-mail address: DEA.Online.Pharmacy.Request@usdoj.gov. Your response to FDA should be sent to the following e-mail address: FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries regarding this letter to DEA and FDA at the e-mail addresses provided.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nWendy C. Woolcock\u003Cbr>\nSpecial Agent in Charge\u003Cbr>\nSpecial Operations Division\u003Cbr>\nDrug Enforcement Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\npremiumlightsupplier.com\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nTO: www.premiumlightsupplier.com\n\nFROM: The United States Food and Drug Administration and The United States Drug Enforcement Administration\n\nRE: Notice of Unlawful Sale of Schedule II Stimulants to United States Consumers Over the Internet\n\nDATE: March 30, 2022\n\nWARNING LETTER\n\nThis is to advise you that based on the United States (U.S.) Drug Enforcement Administration’s (DEA) review, www.premiumlightsupplier.com unlawfully offers to distribute or dispense stimulants that are Schedule II controlled substances, including amphetamine drug products, and advertises their sale in violation of the Ryan Haight Online Pharmacy Consumer Protection Act (RHA), P.L. 110-425 (October 15, 2008), as codified at 21 U.S.C. § 841(h) and § 843(c). In addition, based on the U.S. Food and Drug Administration’s (FDA) review, the FDA has observed that www.premiumlightsupplier.com introduces into interstate commerce amphetamine drug products that are misbranded in violation of sections 301(a), 301(k), and 503(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(k), and 353(b)].\n\nSchedule II stimulants have an acknowledged high potential for abuse, and it is important to address the public health impact of their diversion and nonmedical use. Diversion is the primary source of prescription stimulants for nonmedical use, and nonmedical use is most frequent among young adults and college students. Polysubstance use is common among those who use prescription stimulants nonmedically, with individuals frequently co-using illicit drugs and\u002For prescription opioids. These concerns come against a backdrop of rising mortality from psychostimulant-involved overdoses, which involve illicit stimulants the vast majority of the time, but sometimes involve prescription stimulants.\n\nThe easy availability of these stimulants via the Internet poses additional significant risks to U.S. consumers. Additionally, the sale of misbranded drugs, including misbranded stimulants, poses an inherent risk to consumers who purchase those products. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.\n\nAs set forth more fully in this Warning Letter, we request that you take any necessary corrective action and notify DEA and FDA of any remedial steps that you have taken to address any violations of Federal law. This letter also provides a procedure if you wish to contest this Warning Letter with respect to your website(s). After 15 days, failure to adequately address this matter may result in further action by DEA and FDA including potentially contacting the domain name registrar(s) associated with your website(s) and informing them of your actions.\n\nUnder the RHA, an “online pharmacy” is a “person, entity, or Internet site, whether in the U.S. or abroad, that knowingly or intentionally delivers, distributes, or dispenses, or offers or attempts to deliver, distribute, or dispense, a controlled substance by means of the Internet.” 21 U.S.C. § 802(52)(A) (emphasis added). It is unlawful to knowingly or intentionally “deliver, distribute, or dispense a controlled substance by means of the Internet, except as authorized [by the Controlled Substances Act (CSA)],” or to knowingly or intentionally aid or abet such activity. 21 U.S.C. § 841(h)(1). This includes, for example, knowingly or intentionally “delivering, distributing, or dispensing a controlled substance by means of the Internet by an online pharmacy that is not validly registered” with a modified DEA registration authorizing such activity, see 21 U.S.C. § 841(h)(2)(A), or knowingly or intentionally serving as an “agent, intermediary, or other entity that causes the Internet to be used to bring together a buyer and seller to engage in the dispensing of a controlled substance” without a modified DEA registration. 21 U.S.C. § 841(h)(2)(C).\n\nIn addition, under the RHA, it is also unlawful “for any person to knowingly or intentionally use the Internet, or cause the Internet to be used, to advertise the sale of, or to offer to sell, distribute, or dispense, a controlled substance where such sale, distribution or dispensing is not authorized by [the CSA] or by the Controlled Substances Import and Export Act” (CSIEA). 21 U.S.C. § 843(c)(2)(A). Examples include “knowingly or intentionally causing the placement on the Internet of an advertisement that refers to or directs prospective buyers to Internet sellers of controlled substances” who do not possess a valid modified DEA registration. 21 U.S.C. § 843(c)(2)(B) (with limitations described in 21 U.S.C. § 843(c)(2)(C)).\n\nNo Modified DEA Registration Exists for Your Website(s)\n\nYour website(s) constitutes an “online pharmacy” because it is an Internet site that knowingly or intentionally offers to deliver, distribute, or dispense a controlled substance by means of the Internet. 21 U.S.C. § 802(52). Moreover, as the owner and domain name subscriber responsible for operation of the website(s), you are serving as an agent or other entity that causes the Internet to be used to bring together buyers and sellers for the purpose of dispensing a controlled substance. DEA has determined that you are not in possession of a modified DEA registration authorizing you to engage in such activity. Accordingly, your actions constitute a violation of U.S. law, which are subject to criminal penalties and civil enforcement.\n\nIn addition, you knowingly or intentionally use the Internet to advertise the sale of controlled substances by directing prospective buyers to Internet sellers of controlled substances who do not possess a valid modified DEA registration. You do not possess a valid modified DEA registration authorizing such activity, and your actions do not fall into the exceptions of 21 U.S.C. § 843(c)(2)(C). Therefore, your website(s) is operating in violation of U.S. law, which may be enforced through criminal penalties and civil enforcement.\n\nMisbranded Drug(s)\n\nCertain products offered for sale by www.premiumlightsupplier.com are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body.\n\nFor example, www.premiumlightsupplier.com offers an amphetamine drug product for sale listed as “Adderall 20mg | 30mg.” Adderall is the brand name of an FDA-approved drug for the treatment of attention deficit hyperactive disorder (ADHD) and narcolepsy that is only available by prescription. Using the brand name of the drug product Adderall indicates that this product is intended to treat ADHD and narcolepsy. FDA-approved Adderall bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning indicates that amphetamines, including Adderall, have a high potential for abuse and dependence.\n\nThe FDA-approved product Adderall is a stimulant medication. All stimulants that have been approved for marketing by FDA are limited by an approved new drug application to use under the supervision of a licensed practitioner to administer such drugs. Therefore, Adderall is a prescription drug as defined in section 503(b)(1)(A) of the FD&C Act (21 U.S.C. § 353(b)(1)(A)), because, in light of its toxicity or potential for harmful effects, the method of its use, or the collateral measures necessary for its use, it is not safe for use except under the supervision of a practitioner licensed by law to administer such a drug. By offering the aforementioned drug without requiring a prescription, www.premiumlightsupplier.com jeopardizes patient safety and misbrands the drug under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act [21 U.S.C. § 331(k)]. By offering this drug for sale to U.S. consumers, www.premiumlightsupplier.com is also causing the introduction of a misbranded drug into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. It is your responsibility to ensure that all products you offer for sale on your website(s) are in compliance with Federal law, including but not limited to the RHA and its implementing regulations, as well as the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the RHA and the FD&C Act. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. Nothing in this letter should be deemed to preclude any other action, criminal or civil, by U.S. authorities.\n\nPlease notify DEA and FDA, in writing, within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the RHA and FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\n\nAfter 15 days, DEA and FDA may take any additional actions that they determine to be necessary, potentially including contacting the domain name registrar(s) associated with your website(s) and informing them of your actions. Please note that the transmission of this Warning Letter does not prohibit DEA or FDA from taking any or all other actions permitted by law, including the initiation of civil or criminal proceedings against you, your website(s), or materials that you have intended for distribution.\n\nIf you are not located in the U.S., please note that products that appear to be misbranded drugs may be detained or refused admission. FDA may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\n\nYour response to DEA should be sent to the following e-mail address: DEA.Online.Pharmacy.Request@usdoj.gov. Your response to FDA should be sent to the following e-mail address: FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov. Please direct any inquiries regarding this letter to DEA and FDA at the e-mail addresses provided.\n\nSincerely,\n\n\u002FS\u002F\n\nWendy C. Woolcock\n\nSpecial Agent in Charge\n\nSpecial Operations Division\n\nDrug Enforcement Administration\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","premiumlightsupplier.com","premiumlightsuppliercom-622056-03302022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremiumlightsuppliercom-622056-03302022","2026-10-26T08:09:43.757824+00:00","2022-04-12","622056","2026-08-20T02:01:25.025+00:00","2022-03-30",{"id":300,"raw":301,"subject":305,"body_html":306,"body_text":307,"firm_name":308,"letter_id":309,"created_at":45,"fei_number":20,"letter_url":310,"updated_at":311,"action_type":23,"case_status":24,"posted_date":312,"marcs_cms_no":313,"product_type":130,"closeout_date":20,"issuing_office":119,"recipient_name":314,"body_fetched_at":315,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":316,"medical_device_id":20,"response_letter_date":20},1862,[302,303,304,119,305,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:20:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023\">BYD Precision Manufacture Co., Ltd\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liu Xiaoling\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BYD Precision Manufacture Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Baolong Industrial, No. 3001 Baohe Road; Longgangjiedao\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Longgang Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 5, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Liu Xiaoling:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Shen Haigen, R&amp;D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Process Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic cutting machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated elastic-stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> - automated metal nose piece attachment machines,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> - semi-automated stapler machines, \u003Cstrong>(b)(4)\u003C\u002Fstrong> individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\u003C\u002Fli>\n\t\u003Cli>Your firm provided IQ\u002FOQ\u002FPQ reports for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (equipment number: 40002059), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001993), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (40001169), belt cutting machine (40002176), \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>machine (40001971), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Device Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “\u003Cem>improve the missing content of the program file\u003C\u002Fem>.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\u003C\u002Fp>\n\n\u003Cp>1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\u003C\u002Fp>\n\n\u003Cp>2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\u003C\u002Fp>\n\n\u003Cp>a. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\n\n\u003Cp>3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\u003Cbr>\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\u003Cbr>\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003C\u002Fp>\n\n\u003Cp>a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\nb. Information that was evaluated to determine if an event was reportable.\u003Cbr>\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>Additionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical and Infection Control\u003Cbr>\nDevices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nLisa Van\u003Cbr>\nNova Clinical Solutions\u003Cbr>\n4455 Eastgate Mall, Suite 200\u003Cbr>\nSan Diego, CA 92121\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiu Xiaoling\n\nRecipient Title\n\nGeneral Manager\n\nBYD Precision Manufacture Co., Ltd\n\nBaolong Industrial, No. 3001 Baohe Road; Longgangjiedao\n\nLonggang Qu\n\nShenzhen Shi\n\nGuangdong Sheng, 518116\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 5, 2023\n\nDear Liu Xiaoling:\n\nDuring an inspection of your firm located in Shenzhen, Guangdong, China on May 22, 2023 through May 26, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures BYD Surgical Mask Model FE2111, BYD Surgical Mask Model FE2311B, and BYD N95 Respirator Model DE2322. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Shen Haigen, R&D Engineer and Management Representative dated June 12, 2023 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30.\n\nFor example:\n\nYour firm has not established procedures for design controls and was unable to provide records demonstrating conformance with design input, design output, design review, design verification, design validation, design transfer, design changes, and design history file for the surgical N95 respirators (Model DE2322) and surgical masks (Model FE2311 and Model FE2311B).\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm did not provide procedures for design controls for surgical N95 respirator model DE2322 or surgical mask models FE2311 and 2311B. Your firm indicated that it had a “design control program file” approved December 30, 2019 but only provided design history file for surgical N95 respirator model DE2322.\n\n2. Failure to validate with a high degree of assurance and approve according to established procedures, processes where the results cannot be fully verified by subsequent inspections and tests. Failure to document validation activities and results, as required by 21 CFR 820.75(a).\n\nFor example:\n\nProcess Validation records were requested for the following processes that are used for manufacturing surgical N95 respirators and surgical masks: (b)(4) - automated elastic cutting machines, (b)(4) - automated elastic-stapler machines, (b)(4) - automated stapler machines, (b)(4) - automated metal nose piece attachment machines, (b)(4) - semi-automated stapler machines, (b)(4) individual mask package sealer machines, and elastic band pull test. However, your firm was unable to provide records demonstrating where the results of a process cannot be fully verified by subsequent inspection and test, the process is validated with a high degree of assurance and approved according to established procedures.\n\nYour firm provided IQ\u002FOQ\u002FPQ reports for the (b)(4) semi-automated face mask production machines used for manufacturing surgical N95 respirators and surgical masks; however, your firm was unable to provide a rationale for the sample size used during testing. Additionally, the validation reports were not dated and signed by the individual approving the validation.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm provided validation documents for the (b)(4) machine (equipment number: 40002059), (b)(4) machine (40001993), (b)(4) machine (40001169), belt cutting machine (40002176), (b)(4) machine (40001971), and (b)(4) machine processes (40001984). However, the equipment numbers in the validation documents do not match the equipment numbers of those used in the manufacturing process. In addition, validation documents were not provided for all pieces of manufacturing equipment where there are multiple units. Your firm also did not propose a retrospective review to determine which pieces of manufacturing equipment needed validation.\n\n3. Failure to maintain Device Master Records (DMR’s), as required by 21 CFR 820.181.\n\nFor example:\n\nDevice Master Records (DMRs) for N95 respirator mask or the single-use surgical mask were requested; however, your firm was unable to produce these records for review. Your firm’s Quality Manager stated that the DMR for N95 respirator mask or the single use surgical mask will need to be prepared.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your firm provided a DMR for surgical N95 respirator model DE2326. However, your firm stated during the inspection that only model DE2322 was manufactured and shipped for the U.S. market. A DMR was not provided for surgical N95 respirator model DE2322 or any of the surgical masks. In addition, your firm did not indicate how it would handle products that were released without a DMR and whether there would be training on new procedures.\n\n4. Failure to establish procedures for receiving, reviewing and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)\n\nFor example:\n\nYour firm‘s Customer Feedback Procedure, No. MSP-20-D23-009, Rev. A\u002F0, dated 2020-March-28, does not include a process for determining whether a complaint represents an event which is required to be reported to FDA under part 803, Medical Device Reporting.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You stated that you have modified the customer feedback procedure to “improve the missing content of the program file.” However, no documentation was provided for FDA to evaluate. In addition, you did not indicate whether there will be a retrospective review to determine if any old complaints needed to be reported as MDRs and whether there will be training on the new procedure.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nFor example, during the inspection, your firm identified a partially English-translated version of the document titled “Procedure for the Control of Advisory Notifications and Adverse Event Reporting for Medical Device Products”, MSP-20-D23-006, Ver. A\u002F1, dated 5\u002F11\u002F2020, as its MDR procedure. After reviewing the document, we conclude that it does not contain information that would indicate that it is an MDR procedure created in accordance with the requirements in 21 CFR 803.17. Specifically,\n\n1. The document does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na. There are no definitions of what your firm will consider to be a reportable event under 21 CFR Part 803. The exclusion of definitions from 21 CFR 803.3 for the terms “become aware”, “caused or contributed”, “malfunction”, “MDR reportable event”, and “serious injury”, and the definition for the term “reasonably suggests”, found in 803.20(c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb. The document does not include instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner.\n\n2. The document does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example,\n\na. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\n\nb. The document, as written, does not specify who makes the decision for reporting events to FDA.\n\n3. The document does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the document does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. The circumstances under which your firm must submit initial 30 days, supplement or follow-up, 5 day report and the requirements for such reports.\n\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\n\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\n4. The document does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nAdditionally, based on our records, as of July 13, 2023, there is no evidence that your firm established an active Electronic Submissions Gateway (ESG) production account for the electronic submission of MDR reports.\n\nThe adequacy of your firm’s response cannot be determined at this time. You noted that you are working with your U.S. subsidiary to develop and implement an MDR reporting process. However, there is no procedure available for the FDA to assess its adequacy.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case # 666250 when replying. If you have any questions about the contents of this letter, please contact: Bifeng Qian, M.D., Ph.D. at 301-796-2261.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, M.D., M.B.A., F.A.C.S.\n\nDirector\n\nOHT4: Office of Surgical and Infection Control\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nLisa Van\n\nNova Clinical Solutions\n\n4455 Eastgate Mall, Suite 200\n\nSan Diego, CA 92121","BYD Precision Manufacture Co., Ltd","byd-precision-manufacture-co-ltd-666250-09052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbyd-precision-manufacture-co-ltd-666250-09052023","2026-10-26T08:08:09.787753+00:00","2023-09-12","666250","Liu Xiaoling","2026-08-20T00:41:41.972+00:00","2023-09-05",{"id":318,"raw":319,"subject":40,"body_html":323,"body_text":324,"firm_name":325,"letter_id":326,"created_at":327,"fei_number":20,"letter_url":328,"updated_at":329,"action_type":23,"case_status":24,"posted_date":330,"marcs_cms_no":331,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":332,"body_fetched_at":333,"delivery_method":53,"recipient_title":20,"reference_number":20,"action_taken_date":330,"medical_device_id":20,"response_letter_date":20},3544,[320,321,322,39,40,13,13,13],"\u003Ctime datetime=\"2021-02-12T14:00:00Z\">02\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-12T05:00:00Z\">02\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-vapor-technologies-llc-613229-02122021\">Premium Vapor Technologies LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Travis Pinkerton and Candace Almaguer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Premium Vapor Technologies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 Brushy Creek Road Ste 304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cedar Park\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78613\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vaportec.austin@gmail.com\"> vaportec.austin@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@vapevta.com\"> support@vapevta.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vtawholesale@vapevta.com\"> vtawholesale@vapevta.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>February 12, 2021\u003C\u002Fspan>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Travis Pinkerton and Candace Almaguer:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Fvapevta.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1.&nbsp; Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Cu>\u003Cspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect.&nbsp; A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Our review of https:\u002F\u002Fvapevta.com revealed that you manufacture and offer for sale or distribution\u003Cb> \u003C\u002Fb>to customers in the United States e-liquid products\u003Cb> \u003C\u002Fb>without a marketing authorization order including: Odin’s Mead and Asgard.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 140 products listed with FDA.&nbsp; It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.&nbsp; Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.&nbsp; You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, RW2101495, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301)&nbsp;796-9235 \u003Cspan>or via email at\u003C\u002Fspan> \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>VIA UPS and Electronic Mail\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cc:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Premium Vapor Technologies LLC\u003Cbr>\nAttn: Travis Pinkerton and Candace Almaguer\u003Cbr>\n100 East Whitestone Blvd Ste 148\u003Cbr>\n#343\u003Cbr>\nCedar Park, TX&nbsp; 78613\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GoDaddy.com, LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@godaddy.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Shopify, Inc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@shopify.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTravis Pinkerton and Candace Almaguer\n\nPremium Vapor Technologies LLC\n\n300 Brushy Creek Road Ste 304\n\nCedar Park, TX 78613\n\nUnited States\n\nvaportec.austin@gmail.com\n\nsupport@vapevta.com\n\nvtawholesale@vapevta.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 12, 2021\n\nWARNING LETTER\n\nDear Travis Pinkerton and Candace Almaguer:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Fvapevta.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of https:\u002F\u002Fvapevta.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Odin’s Mead and Asgard.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 140 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101495, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nPremium Vapor Technologies LLC\n\nAttn: Travis Pinkerton and Candace Almaguer\n\n100 East Whitestone Blvd Ste 148\n\n#343\n\nCedar Park, TX 78613\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Premium Vapor Technologies LLC","premium-vapor-technologies-llc-613229-02122021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-vapor-technologies-llc-613229-02122021","2026-10-26T08:09:43.721663+00:00","2021-02-12","613229","Travis Pinkerton and Candace Almaguer","2026-08-20T03:23:22.913+00:00",{"id":335,"raw":336,"subject":98,"body_html":340,"body_text":341,"firm_name":342,"letter_id":343,"created_at":103,"fei_number":20,"letter_url":344,"updated_at":345,"action_type":23,"case_status":24,"posted_date":346,"marcs_cms_no":347,"product_type":108,"closeout_date":20,"issuing_office":277,"recipient_name":348,"body_fetched_at":349,"delivery_method":350,"recipient_title":20,"reference_number":20,"action_taken_date":351,"medical_device_id":20,"response_letter_date":20},356,[337,338,339,277,98,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-15T05:00:00Z\">01\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-smart-african-food-llc-721634-01152026\">The Great Smart African Food LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul Yehu Nahanda\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Great Smart African Food LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10015 Lorain Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cleveland\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44111-5430\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northern Border Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 15, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 721634\u003C\u002Fp>\u003Cp>Dear Mr. Nahanda:\u003C\u002Fp>\u003Cp>On October 23, 2025, through December 16, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of The Great Smart African Food LLC located at 10015 Lorain Ave, Cleveland, OH 44111-5430. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-ruleforeign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>We have not received your response to the Form FDA 483a issued on 12\u002F16\u002F2025.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods you import from the foreign supplier(s) indicated in the attached lists, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Maize Flour, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Peanut Butter Biscuits, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Dried Milk, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>During our inspection, you provided the following documents: invoices, Bills of Lading, and Phytosanitary Certificates. You stated that you obtained these from your foreign supplier. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Katharine Oaks, Compliance Officer, Division of Northern Border Imports via email at Katharine.Oaks@fda.hhs.gov. Please reference CMS # 721634 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Keith J. Jasukaitis\u003Cbr>Program Division Director\u003Cbr>Division of Northern Border\u003Cbr>Imports\u003Cbr>300 River Place, 5th Floor\u003Cbr>Detroit MI 48207\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Paul Yehu Nahanda\n\nRecipient Title\n\nOwner\n\nThe Great Smart African Food LLC\n\n10015 Lorain Ave\n\nCleveland, OH 44111-5430\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nDivision of Northern Border Imports\n\nUnited States\n\nJanuary 15, 2026\nWARNING LETTER\nRe: CMS # 721634\nDear Mr. Nahanda:\nOn October 23, 2025, through December 16, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of The Great Smart African Food LLC located at 10015 Lorain Ave, Cleveland, OH 44111-5430. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-ruleforeign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nWe have not received your response to the Form FDA 483a issued on 12\u002F16\u002F2025.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods you import from the foreign supplier(s) indicated in the attached lists, including each of the following foods:\nMaize Flour, imported from (b)(4), located in (b)(4)\nPeanut Butter Biscuits, imported from (b)(4), located in (b)(4)\nDried Milk, imported from (b)(4), located in (b)(4)\nDuring our inspection, you provided the following documents: invoices, Bills of Lading, and Phytosanitary Certificates. You stated that you obtained these from your foreign supplier. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Katharine Oaks, Compliance Officer, Division of Northern Border Imports via email at Katharine.Oaks@fda.hhs.gov. Please reference CMS # 721634 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nKeith J. Jasukaitis\nProgram Division Director\nDivision of Northern Border\nImports\n300 River Place, 5th Floor\nDetroit MI 48207","The Great Smart African Food LLC","great-smart-african-food-llc-721634-01152026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreat-smart-african-food-llc-721634-01152026","2026-10-26T08:08:49.584001+00:00","2026-02-03","721634","Mr. Paul Yehu Nahanda","2026-08-19T07:15:52.434+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2026-01-15",{"id":353,"raw":354,"subject":358,"body_html":359,"body_text":360,"firm_name":361,"letter_id":362,"created_at":125,"fei_number":20,"letter_url":363,"updated_at":364,"action_type":23,"case_status":24,"posted_date":365,"marcs_cms_no":366,"product_type":27,"closeout_date":20,"issuing_office":287,"recipient_name":367,"body_fetched_at":368,"delivery_method":369,"recipient_title":20,"reference_number":20,"action_taken_date":365,"medical_device_id":20,"response_letter_date":20},1396,[355,356,357,287,358,13,13,13],"\u003Ctime datetime=\"2024-07-02T13:20:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-02T04:00:00Z\">07\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-manufacturing-products-llc-678912-07022024\">Premier Manufacturing Products, LLC\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Atofil@mtdst.us\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James P. Morrissette\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Premier Manufacturing Products, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>912 46th Lane Unit 204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cape Coral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33904\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:JPM@premiermt.com\"> JPM@premiermt.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 2, 2024\u003Cbr>\n\u003Cbr>\nChristopher Mitchell, COO\u003Cbr>\nIT@MTDST.US\u003Cbr>\nCSM@premierMT.com\u003C\u002Fp>\n\n\u003Cp>Deborah L. Lloyd\u003Cbr>\nPremier Manufacturing Products, LLC\u003Cbr>\n730 NE 19th Place,\u003Cbr>\nCape Coral, FL 33909\u003Cbr>\nDlloyd@atofil.us\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 678912\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear James Morrissette, Christopher Mitchell and Deborah Lloyd:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed labeling obtained from an inspection of your drug manufacturing facility, Atofil, LLC, from January 22 to 25, 2024, from which FDA observed that you offer numerous Tianeptine products, specifically “Tianaa Red,” “Tianaa White,” and “Tianaa Green” for sale in the United States. Based on our review, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of the product labeling obtained during the inspection, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your email blast promotional material, which links back to your website https:\u002F\u002Fmtbrands.com\u002Ftianaa, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The Wait For Tianaa is Over . . . LET US TAKE YOU THERE . . . Tianaa is a proprietary blend of Natural Herbs and Nootropics created to deliver the unparalleled pick up, clarity, relaxation, and relief”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S.\u003Cbr>\nCaptain, U.S Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nAtofil@mtdst.us\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJames P. Morrissette\n\nRecipient Title\n\nCEO\n\nPremier Manufacturing Products, LLC\n\n912 46th Lane Unit 204\n\nCape Coral, FL 33904\n\nUnited States\n\nJPM@premiermt.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nJuly 2, 2024\n\nChristopher Mitchell, COO\n\nIT@MTDST.US\n\nCSM@premierMT.com\n\nDeborah L. Lloyd\n\nPremier Manufacturing Products, LLC\n\n730 NE 19th Place,\n\nCape Coral, FL 33909\n\nDlloyd@atofil.us\n\nRE: 678912\n\nDear James Morrissette, Christopher Mitchell and Deborah Lloyd:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed labeling obtained from an inspection of your drug manufacturing facility, Atofil, LLC, from January 22 to 25, 2024, from which FDA observed that you offer numerous Tianeptine products, specifically “Tianaa Red,” “Tianaa White,” and “Tianaa Green” for sale in the United States. Based on our review, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nUnapproved New Drugs\n\nBased on our review of the product labeling obtained during the inspection, your “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your email blast promotional material, which links back to your website https:\u002F\u002Fmtbrands.com\u002Ftianaa, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\n“The Wait For Tianaa is Over . . . LET US TAKE YOU THERE . . . Tianaa is a proprietary blend of Natural Herbs and Nootropics created to deliver the unparalleled pick up, clarity, relaxation, and relief”\n\nYour “Tianaa Red,” “Tianaa White,” and “Tianaa Green” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","Premier Manufacturing Products, LLC","premier-manufacturing-products-llc-678912-07022024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremier-manufacturing-products-llc-678912-07022024","2026-10-26T08:09:43.462221+00:00","2024-07-02","678912","James P. Morrissette","2026-08-20T00:00:07.13+00:00","Via Email Atofil@mtdst.us",{"id":371,"raw":372,"subject":377,"body_html":378,"body_text":379,"firm_name":380,"letter_id":381,"created_at":103,"fei_number":20,"letter_url":382,"updated_at":383,"action_type":23,"case_status":24,"posted_date":384,"marcs_cms_no":385,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":20,"body_fetched_at":386,"delivery_method":387,"recipient_title":20,"reference_number":20,"action_taken_date":388,"medical_device_id":20,"response_letter_date":20},282,[373,374,375,11,376,13,13,13],"\u003Ctime datetime=\"2026-03-05T05:00:00Z\">03\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-health-management-inc-dba-premium-health-721474-02202026\">Premium Health Management Inc. dba Premium Health\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)\u003Cbr \u002F>\r\n","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Premium Health Management Inc. dba Premium Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1800 E. Garry Ave. Suite 224\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Ana\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cs@premiumhealth.us\"> cs@premiumhealth.us \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Premium Health:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fpremiumhealth.us, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Premium Health” on the pictured label, suggesting Premium Health is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Premium Health is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“generic compounded medication”\u003C\u002Fli>\u003Cli>“Semaglutide (the active ingredient used in Ozempic® and Wegovy®)”\u003C\u002Fli>\u003Cli>“Tirzepatide (active ingredient used in Mounjaro®)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPremium Health Management Inc. dba Premium Health\n\n1800 E. Garry Ave. Suite 224\n\nSanta Ana, CA 92705\n\nUnited States\n\ncs@premiumhealth.us\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nPremium Health:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fpremiumhealth.us, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Premium Health” on the pictured label, suggesting Premium Health is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Premium Health is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“generic compounded medication”\n“Semaglutide (the active ingredient used in Ozempic® and Wegovy®)”\n“Tirzepatide (active ingredient used in Mounjaro®)”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Premium Health Management Inc. dba Premium Health","premium-health-management-inc-dba-premium-health-721474-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-health-management-inc-dba-premium-health-721474-02202026","2026-10-26T08:09:43.649341+00:00","2026-03-05","721474","2026-08-19T04:52:43.619+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-20",{"id":390,"raw":391,"subject":144,"body_html":395,"body_text":396,"firm_name":397,"letter_id":398,"created_at":45,"fei_number":20,"letter_url":399,"updated_at":400,"action_type":23,"case_status":24,"posted_date":401,"marcs_cms_no":402,"product_type":27,"closeout_date":20,"issuing_office":287,"recipient_name":403,"body_fetched_at":404,"delivery_method":111,"recipient_title":20,"reference_number":20,"action_taken_date":405,"medical_device_id":20,"response_letter_date":20},1937,[392,393,394,287,144,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-09T04:00:00Z\">08\u002F09\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalmco-llc-previously-named-ketomi-llc-663668-08092023\">CalmCo LLC previously named Ketomi LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Keith Page\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>CalmCo LLC previously named Ketomi LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1215 Sarasota Center Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sarasota\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>34240\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Keith@calmco.com\"> Keith@calmco.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customercare@coliccalm.com\"> customercare@coliccalm.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 9, 2023\u003C\u002Fp>\n\n\u003Cp>RE: 663668\u003C\u002Fp>\n\n\u003Cp>Dear Keith Page:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.coliccalm.com in May 2023. The FDA has observed that your firm offers “Colic Calm,” and “Colic Calm +,” for sale in the United States. Based on our review of your website and product labels, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Please also reference warning letter 654226, issued on July 26, 2023, to Denison Pharmaceuticals, LLC, that summarized significant violations of current good manufacturing practice (CGMP) regulations for its finished pharmaceuticals.\u003C\u002Fp>\n\n\u003Cp>Your “Colic Calm,” and “Colic Calm +” products are particularly concerning from a public health perspective because of these CGMP violations and because they are directed for use in infants.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of the product labels and your website www.coliccalm.com, your “Colic Calm,” and “Colic Calm +” products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Colic Calm\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From the product label:\u003Cbr>\n• “For Symptomatic relief of infant Colic, Gas &amp; Reflux”\u003Cbr>\n• “Temporarily relieves the symptoms of infant: colic · gas · reflux · upset stomach · bloating · hiccups”\u003C\u002Fp>\n\n\u003Cp>From the website www.coliccalm.com:\u003Cbr>\n• “Colic Calm eases baby’s discomfort often associated with gas, colic, hiccups and teething. Our gentle liquid formula is the #1 selling gripe water for infant gas &amp; colic relief.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Colic Calm +\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>From the product label:\u003Cbr>\n• “For Symptomatic relief of infant Colic, Gas &amp; Reflux”\u003Cbr>\n• “Temporarily relieves the symptoms of infant: colic · gas · reflux · upset stomach · bloating · hiccups”\u003C\u002Fp>\n\n\u003Cp>From the website www.coliccalm.com:\u003Cbr>\n• “Colic Calm® Plus is a professional strength formulation developed for babies that need extra help. Our Plus formula is enhanced with additional gas absorption properties . . . four more homeopathic remedies for added digestive support . . . amazing healing properties to quickly and safely eliminate the symptoms of infant gas, colic and upset stomach.”\u003C\u002Fp>\n\n\u003Cp>Your “Colic Calm,” and “Colic Calm +,” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that “Colic Calm,” and “Colic Calm +,” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKeith Page\n\nCalmCo LLC previously named Ketomi LLC\n\n1215 Sarasota Center Blvd\n\nSarasota, FL 34240\n\nUnited States\n\nKeith@calmco.com\n\ncustomercare@coliccalm.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nAugust 9, 2023\n\nRE: 663668\n\nDear Keith Page:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.coliccalm.com in May 2023. The FDA has observed that your firm offers “Colic Calm,” and “Colic Calm +,” for sale in the United States. Based on our review of your website and product labels, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nPlease also reference warning letter 654226, issued on July 26, 2023, to Denison Pharmaceuticals, LLC, that summarized significant violations of current good manufacturing practice (CGMP) regulations for its finished pharmaceuticals.\n\nYour “Colic Calm,” and “Colic Calm +” products are particularly concerning from a public health perspective because of these CGMP violations and because they are directed for use in infants.\n\nUnapproved New Drugs\n\nBased on a review of the product labels and your website www.coliccalm.com, your “Colic Calm,” and “Colic Calm +” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nColic Calm\n\nFrom the product label:\n\n• “For Symptomatic relief of infant Colic, Gas & Reflux”\n\n• “Temporarily relieves the symptoms of infant: colic · gas · reflux · upset stomach · bloating · hiccups”\n\nFrom the website www.coliccalm.com:\n\n• “Colic Calm eases baby’s discomfort often associated with gas, colic, hiccups and teething. Our gentle liquid formula is the #1 selling gripe water for infant gas & colic relief.”\n\nColic Calm +\n\nFrom the product label:\n\n• “For Symptomatic relief of infant Colic, Gas & Reflux”\n\n• “Temporarily relieves the symptoms of infant: colic · gas · reflux · upset stomach · bloating · hiccups”\n\nFrom the website www.coliccalm.com:\n\n• “Colic Calm® Plus is a professional strength formulation developed for babies that need extra help. Our Plus formula is enhanced with additional gas absorption properties . . . four more homeopathic remedies for added digestive support . . . amazing healing properties to quickly and safely eliminate the symptoms of infant gas, colic and upset stomach.”\n\nYour “Colic Calm,” and “Colic Calm +,” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that “Colic Calm,” and “Colic Calm +,” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","CalmCo LLC previously named Ketomi LLC","calmco-llc-previously-named-ketomi-llc-663668-08092023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalmco-llc-previously-named-ketomi-llc-663668-08092023","2026-10-26T08:08:10.480013+00:00","2023-08-15","663668","Keith Page","2026-08-20T00:47:27.447+00:00","2023-08-09",32,{"510k":408,"classification":409,"enforcement":410,"event":411,"event_backfill":412,"pma":413,"warning_letter":414},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]